This curriculum vitae summarizes the career and qualifications of Dr. Hava Karsenty Avraham. It lists her education, including a B.S. in Biology from Hebrew University in 1977 and a Ph.D. in General & Tumor Immunology from Hebrew University in 1982. It then details her various faculty appointments at institutions including Harvard Medical School and Northeastern University. The CV also outlines her grant funding, publications, teaching experience, and honors received throughout her career in immunology and cancer research.
Dr. Simon Christopher Robson is a gastroenterologist and hepatologist currently working as the Charlotte F. and Irving W. Rabb Professor of Medicine at Harvard Medical School. He received his medical degrees from universities in South Africa and postdoctoral training in the UK and South Africa. His CV details his clinical and research positions held at various hospitals, including his current roles at Beth Israel Deaconess Medical Center. It also lists his extensive publications, honors received, and history of leading and participating in numerous funded research projects related to purinergic signaling and transplantation.
The document discusses prognostic indicators for idiopathic pulmonary fibrosis (IPF). Baseline factors that are associated with increased mortality risk include low diffusing capacity of the lung for carbon monoxide (DLCO), increased alveolar-arterial oxygen gradient (A-a), desaturation during the 6-minute walk test, pulmonary hypertension, and honeycombing on high-resolution computed tomography (HRCT). Dynamic predictors of mortality include decline in forced vital capacity (FVC), DLCO, and worsening dyspnea. However, prognostic indicators do not fully predict disease progression for individual patients with IPF.
Primary hyperparathyroidism is caused by excessive secretion of parathyroid hormone from one or more parathyroid glands. Historically, it manifested as a disease of bone, kidney stones, and other complications. Now, it often presents with only mildly elevated calcium and parathyroid hormone levels. Parathyroid hormone in excessive amounts can be harmful, but in controlled doses it acts as an osteoanabolic agent and increases bone mineral density. Teriparatide, a parathyroid hormone treatment, reduces fracture risk by stimulating new bone formation within an "anabolic window". A new analogue, abaloparatide, may also have osteoanabolic properties. Guidelines provide criteria for surgery versus monitoring in asymptomatic
This curriculum vitae summarizes the career and qualifications of Dr. Yu-Lin Lin. He is a clinical assistant professor of oncology at National Taiwan University Hospital specializing in gastrointestinal and lung cancers. He received his M.D. from Chung Shan Medical University in 1999 and Ph.D. from National Taiwan University in 2014. He has published over 25 papers including some in high impact journals like Lancet Oncology. His research focuses on tumor biology and molecular mechanisms of cancer.
A comparative analysis of biochemical and hematological parameters in diabeti...amsjournal
This study evaluated the biochemical and the hematological parameters in diabetic and non- diabetic patients. The measured biochemical parameters were fasting blood sugar, serum alanine aminotransferase (SGPT/ALT), total cholesterol, urea, creatinine and hematological parameters were hemoglobin, total white blood cell, neutrophil, lymphocyte,monocyte, eosinophil and ESR. There were 403 diabetic and 320 non-diabetic subjects included in this study and the study was carried out in BIRDEM (Bangladesh Institute of Research & Rehabilitation in Diabetes, Endocrine and Metabolic Disorders) General Hospital). It was observed that the mean values of SGPT/ALT (p<0.001),><0.001)><0.001)><0.001),><0.004),><0.001) of hematological parameters were significantly higher in diabetic patients than in the non-diabetic patients. In univariate analysis, all biochemical parameters and only four hematological parameters were found significantly associated with fasting blood sugar after adjusted with age and sex. The fasting blood sugar correlates highly with the other biochemical parameters but less or none with the hematological parameters. Our findings demonstrated that control of increased biochemical parameters and abnormal hematological levels in the early stage of diabetes mellitus may help the patients to raise quality of life.
This document summarizes a study that investigated factors affecting intensive care unit (ICU) and long-term mortality in patients who underwent tracheostomy due to respiratory failure. The study included 115 patients who received percutaneous or surgical tracheostomy between 2016-2019. It found that hospital mortality was higher in patients with growth of the resistant bacteria Acinetobacter baumannii. However, long-term survival was not affected by the growth of A. baumannii. Patients who had a history of cerebrovascular accident had lower long-term survival. The study concluded that rational antibiotic therapy and prevention/treatment of cerebrovascular accidents could help improve short and long-term survival in these patients.
Total and Cause-Specific Mortality of U.S. Nurses Working Rotating Night ShiftsEmergency Live
Know more on http://www.emergency-live.com
Total and Cause-Specific Mortality of U.S.
Nurses Working Rotating Night Shifts
Fangyi Gu, MD, ScD, Jiali Han, PhD, Francine Laden, ScD, An Pan, PhD, Neil E. Caporaso, MD,
Meir J. Stampfer, MD, DrPH, Ichiro Kawachi, MD, PhD, Kathryn M. Rexrode, MD, MPH,
Walter C. Willett,MD, DrPH, Susan E. Hankinson, ScD, Frank E. Speizer,MD, Eva S. Schernhammer,MD, DrPH
Background: Rotating night shift work imposes circadian strain and is linked to the risk of several
chronic diseases.
Purpose: To examine associations between rotating night shift work and all-cause; cardiovascular
disease (CVD); and cancer mortality in a prospective cohort study of 74,862 registered U.S. nurses
from the Nurses’ Health Study.
Methods: Lifetime rotating night shift work (defined as Z3 nights/month) information was
collected in 1988. During 22 years (1988–2010) of follow-up, 14,181 deaths were documented,
including 3,062 CVD and 5,413 cancer deaths. Cox proportional hazards models estimated
multivariable-adjusted hazard ratios (HRs) and 95% CIs.
Results: All-cause and CVD mortality were significantly increased among women withZ5 years of
rotating night shift work, compared to women who never worked night shifts. Specifically, for
women with 6–14 and Z15 years of rotating night shift work, the HRs were 1.11 (95% CI¼1.06,
1.17) and 1.11 (95% CI¼1.05, 1.18) for all-cause mortality and 1.19 (95% CI¼1.07, 1.33) and 1.23
(95% CI¼1.09, 1.38) for CVD mortality. There was no significant association between rotating night
shift work and all-cancer mortality (HRZ15years¼1.08, 95% CI¼0.98, 1.19) or mortality of any
individual cancer, with the exception of lung cancer (HRZ15years¼1.25, 95% CI¼1.04, 1.51).
Conclusions: Women working rotating night shifts for Z5 years have a modest increase in allcause
and CVD mortality; those working Z15 years of rotating night shift work have a modest
increase in lung cancer mortality. These results add to prior evidence of a potentially detrimental
effect of rotating night shift work on health and longevity.
(Am J Prev Med 2015;](]):]]]–]]]) & 2015 American Journal of Preventive Medicine. All rights reserved.
The book Cardiac Drugs presents an evidence-based approach towards the pharmacologic agents that are used in various clinical conditions in cardiovascular medicine.
Dr. Simon Christopher Robson is a gastroenterologist and hepatologist currently working as the Charlotte F. and Irving W. Rabb Professor of Medicine at Harvard Medical School. He received his medical degrees from universities in South Africa and postdoctoral training in the UK and South Africa. His CV details his clinical and research positions held at various hospitals, including his current roles at Beth Israel Deaconess Medical Center. It also lists his extensive publications, honors received, and history of leading and participating in numerous funded research projects related to purinergic signaling and transplantation.
The document discusses prognostic indicators for idiopathic pulmonary fibrosis (IPF). Baseline factors that are associated with increased mortality risk include low diffusing capacity of the lung for carbon monoxide (DLCO), increased alveolar-arterial oxygen gradient (A-a), desaturation during the 6-minute walk test, pulmonary hypertension, and honeycombing on high-resolution computed tomography (HRCT). Dynamic predictors of mortality include decline in forced vital capacity (FVC), DLCO, and worsening dyspnea. However, prognostic indicators do not fully predict disease progression for individual patients with IPF.
Primary hyperparathyroidism is caused by excessive secretion of parathyroid hormone from one or more parathyroid glands. Historically, it manifested as a disease of bone, kidney stones, and other complications. Now, it often presents with only mildly elevated calcium and parathyroid hormone levels. Parathyroid hormone in excessive amounts can be harmful, but in controlled doses it acts as an osteoanabolic agent and increases bone mineral density. Teriparatide, a parathyroid hormone treatment, reduces fracture risk by stimulating new bone formation within an "anabolic window". A new analogue, abaloparatide, may also have osteoanabolic properties. Guidelines provide criteria for surgery versus monitoring in asymptomatic
This curriculum vitae summarizes the career and qualifications of Dr. Yu-Lin Lin. He is a clinical assistant professor of oncology at National Taiwan University Hospital specializing in gastrointestinal and lung cancers. He received his M.D. from Chung Shan Medical University in 1999 and Ph.D. from National Taiwan University in 2014. He has published over 25 papers including some in high impact journals like Lancet Oncology. His research focuses on tumor biology and molecular mechanisms of cancer.
A comparative analysis of biochemical and hematological parameters in diabeti...amsjournal
This study evaluated the biochemical and the hematological parameters in diabetic and non- diabetic patients. The measured biochemical parameters were fasting blood sugar, serum alanine aminotransferase (SGPT/ALT), total cholesterol, urea, creatinine and hematological parameters were hemoglobin, total white blood cell, neutrophil, lymphocyte,monocyte, eosinophil and ESR. There were 403 diabetic and 320 non-diabetic subjects included in this study and the study was carried out in BIRDEM (Bangladesh Institute of Research & Rehabilitation in Diabetes, Endocrine and Metabolic Disorders) General Hospital). It was observed that the mean values of SGPT/ALT (p<0.001),><0.001)><0.001)><0.001),><0.004),><0.001) of hematological parameters were significantly higher in diabetic patients than in the non-diabetic patients. In univariate analysis, all biochemical parameters and only four hematological parameters were found significantly associated with fasting blood sugar after adjusted with age and sex. The fasting blood sugar correlates highly with the other biochemical parameters but less or none with the hematological parameters. Our findings demonstrated that control of increased biochemical parameters and abnormal hematological levels in the early stage of diabetes mellitus may help the patients to raise quality of life.
This document summarizes a study that investigated factors affecting intensive care unit (ICU) and long-term mortality in patients who underwent tracheostomy due to respiratory failure. The study included 115 patients who received percutaneous or surgical tracheostomy between 2016-2019. It found that hospital mortality was higher in patients with growth of the resistant bacteria Acinetobacter baumannii. However, long-term survival was not affected by the growth of A. baumannii. Patients who had a history of cerebrovascular accident had lower long-term survival. The study concluded that rational antibiotic therapy and prevention/treatment of cerebrovascular accidents could help improve short and long-term survival in these patients.
Total and Cause-Specific Mortality of U.S. Nurses Working Rotating Night ShiftsEmergency Live
Know more on http://www.emergency-live.com
Total and Cause-Specific Mortality of U.S.
Nurses Working Rotating Night Shifts
Fangyi Gu, MD, ScD, Jiali Han, PhD, Francine Laden, ScD, An Pan, PhD, Neil E. Caporaso, MD,
Meir J. Stampfer, MD, DrPH, Ichiro Kawachi, MD, PhD, Kathryn M. Rexrode, MD, MPH,
Walter C. Willett,MD, DrPH, Susan E. Hankinson, ScD, Frank E. Speizer,MD, Eva S. Schernhammer,MD, DrPH
Background: Rotating night shift work imposes circadian strain and is linked to the risk of several
chronic diseases.
Purpose: To examine associations between rotating night shift work and all-cause; cardiovascular
disease (CVD); and cancer mortality in a prospective cohort study of 74,862 registered U.S. nurses
from the Nurses’ Health Study.
Methods: Lifetime rotating night shift work (defined as Z3 nights/month) information was
collected in 1988. During 22 years (1988–2010) of follow-up, 14,181 deaths were documented,
including 3,062 CVD and 5,413 cancer deaths. Cox proportional hazards models estimated
multivariable-adjusted hazard ratios (HRs) and 95% CIs.
Results: All-cause and CVD mortality were significantly increased among women withZ5 years of
rotating night shift work, compared to women who never worked night shifts. Specifically, for
women with 6–14 and Z15 years of rotating night shift work, the HRs were 1.11 (95% CI¼1.06,
1.17) and 1.11 (95% CI¼1.05, 1.18) for all-cause mortality and 1.19 (95% CI¼1.07, 1.33) and 1.23
(95% CI¼1.09, 1.38) for CVD mortality. There was no significant association between rotating night
shift work and all-cancer mortality (HRZ15years¼1.08, 95% CI¼0.98, 1.19) or mortality of any
individual cancer, with the exception of lung cancer (HRZ15years¼1.25, 95% CI¼1.04, 1.51).
Conclusions: Women working rotating night shifts for Z5 years have a modest increase in allcause
and CVD mortality; those working Z15 years of rotating night shift work have a modest
increase in lung cancer mortality. These results add to prior evidence of a potentially detrimental
effect of rotating night shift work on health and longevity.
(Am J Prev Med 2015;](]):]]]–]]]) & 2015 American Journal of Preventive Medicine. All rights reserved.
The book Cardiac Drugs presents an evidence-based approach towards the pharmacologic agents that are used in various clinical conditions in cardiovascular medicine.
Role of ayurveda in the management of cancerDr Joban
this pdf contains a compilation of various presentations and papers to get an idea how Ayurved -Panchakarma- Herbal treatment can be helpful to combat Cancer, chemotherapy, Radio therapy hazards, antitumor activities of plants, role of Ayurveda diet in prevention of cancer
Robert C. Shepard has extensive experience in cancer research and clinical oncology spanning over 40 years. He received his MD from Duke University and has held academic and clinical positions at several prestigious institutions. Currently, he works as a consultant in oncology drug development and clinical trials. He has led numerous clinical trials for both pharmaceutical and biotech companies and has published extensively in peer-reviewed journals. His expertise includes all phases of clinical trial design and implementation.
This document discusses the need for improved evidence-based searching capabilities at the intersection of genetics and human genome variation research. It notes that while genetics and clinical evidence sources exist separately, the integration of the two fields is lacking. It then surveys some current tools that provide an interface for searching genetics and evidence-based medicine, but suggests more specialized resources are still needed. The document concludes by proposing further developments like centralized test registries and technologies to map genomic data to clinical pathways based on evidence-based standards.
This curriculum vitae outlines the education and career of Dr. Edgar Lichstein, including his medical training, residencies, fellowships, military service, licenses, appointments, memberships, awards, grants, presentations, and publications. It details his roles as a professor, researcher, and leader in departments of medicine and cardiology over his 50+ year career at institutions including NYU, SUNY, and Maimonides Medical Center.
A cross-sectional study on the prevalence of cardiovascular risk factors amon...Jameel Hijazeen
YouTube Video of me presentation these results: http://www.youtube.com/watch?v=YocIOa-5eI8
By Jameel Khaleel Hijazeen (1); Oday Zayid Al-Ma'aitah (1); Mahmoud Yaseen Abuznaid, MD (2); Ahmed Nader Abo.sharak (1); Khaled Ali AlShar' (1); Imad Farjou, MD, PhD (3).
[1] Sixth-year medical students, Faculty of Medicine, Mu'tah University, Karak, Jordan.
[2] Intern, Al-Bashir Teaching Hospital, Amman, Jordan.
[3] Department of Pharmacology, Faculty of Medicine, Mu'tah University, Karak, Jordan.
طلاب السنة السادسة: جميل خليل حجازين، عدي زايد المعايطة ، احمد نادر ابوشرخ، خالد علي الشرع.
طبيب إمتياز، مستشفى البشير: محمود ياسين أبوزنيد.
الأستاذ المشرف: عماد فرجو.
----------------------------------------------------------------
It was presented by me, Jameel Khaleel Hijazeen, sixth-year medical student at Mu'tah University, today, April 11th, 2013, at the 9th Scientific Conference of the Faculty of Medicine at Mu'tah University, Karak, Jordan.
There is always something better! Especially when you are doing something you never did before. Therefore, any feedback is more than welcome.
Some photos and more details about this research and the conference: http://amanfrommoab.com/2013/04/11/the-ninth-scientific-conference-of-the-faculty-of-medicine-at-mutah-university-karak-jordan-april-3-4-2013-2/
This document summarizes the implications of COVID-19 for preventing and treating thrombotic complications. It was endorsed by several thrombosis societies and signed by over 60 experts. The key points are:
1) COVID-19 infection is associated with a prothrombotic state and increased risk of thrombotic complications including pulmonary embolism, deep vein thrombosis, ischemic strokes and arterial thromboses.
2) Clinicians should consider prophylactic anticoagulation for hospitalized COVID-19 patients, especially those with elevated D-dimer or inflammatory markers or who are immobilized.
3) Patients with confirmed VTE or arterial events should receive full anticoagulation treatment. Long-term
The document summarizes a study that aimed to predict clinical failure in patients with metastatic prostate cancer by identifying genes related to prostate cancer. Researchers analyzed gene expression levels of androgen receptor, estrogen receptor, and stem cell markers in cancer and stromal cells collected via laser capture microdissection from biopsy samples of 76 patients. Logistic regression analysis showed that expression of Sox2, Her2, and CRP in cancer cells and AR and ER in stromal cells highly predicted prostate-specific antigen recurrence. Ten factors were identified as prognostic for cancer-specific survival, including expression of Oct1, TRIM36, Sox2, c-Myc, AR, Klf4, ER, and clinical parameters. Patients were divided into risk
cancer becoming major death reason throughout the world. modern medicne is not upto mark in treating cancer because of drug resistance and many side effects. there is necessary for multi target drug therapy with less side efffects which can be only possible through ayurveda through proper research. we have identified multi target drug therapy either by single plant derivatives or by combination of synergistic plant derivatives to target different pathways of cancer cell progression at a time. tinosporin berberibe , curcumin, ellagic acid , and other derivatives derived from same herbs like essential oil, bhasma of same herb and other derivatives combined together in dose dependent ratio has shown good activity against cancer cell progression and survival
This document discusses using proteomics and metabolomics techniques to identify biomarkers for early detection of Amyotrophic Lateral Sclerosis (ALS). It describes previous proteomics studies that identified three biomarkers in CSF and interest in cystatin C as a diagnostic biomarker. Metabolomics studies using NMR on CSF have also found 17 relevant metabolites and perturbations in glucose metabolism. The conclusion is that proteomics and metabolomics show promise as techniques for early ALS detection but require further validation studies.
This curriculum vitae summarizes the career and qualifications of Joseph P. Hanna M.D. It details his employment history including roles at MetroHealth Medical Center and Case Western Reserve University. It also lists his appointments, licensure, education, research funding, publications, professional affiliations and committees. Dr. Hanna is currently an Associate Professor at Case Western Reserve University specializing in neurology with a focus on stroke.
This document summarizes a study that aimed to identify subtypes of type 2 diabetes (T2D) based on clinical characteristics before diagnosis and determine if genetic risk factors differ between the subtypes. The study used clustering analysis to group 832 T2D cases into two clusters based on metabolic and anthropometric measurements. Cox proportional hazards models were then used to test if T2D genetic risk factors differed between the clusters. The clustering resulted in two clusters with cluster one having a higher percentage of women and higher values for waist-to-hip ratio, HDL, and fasting insulin. No statistically significant differences were found in genetic risk factors between the clusters, though adiposity genes were most associated with T2D risk, suggesting an interaction
This curriculum vitae summarizes the career and qualifications of Dr. Emad Aziz, an Associate Professor of Medicine at Mount Sinai specializing in cardiac electrophysiology. It details his medical training and education in Egypt and the United States, including fellowships in cardiology and electrophysiology. It also lists his professional experience, teaching responsibilities, licenses, certifications, publications, and professional society memberships.
This curriculum vitae outlines the educational qualifications and professional experience of Saeed Saeed Alghamdi. He holds a PhD in Toxicology from the University of London and has over 20 years of experience working as a professor of Pharmacology and Toxicology. He has extensive research experience studying the toxic effects of organic solvents and heavy metals. He has published several articles and books on topics related to toxicology.
Obesity in CKD and Renal Transplantation 2017Meguid Nahas
This document discusses obesity and chronic kidney disease (CKD). It notes that obesity is associated with an increased risk of CKD and accelerated progression of CKD. While weight loss is generally recommended for obese patients with CKD, forced weight loss on dialysis can be harmful and is not associated with improved post-transplant outcomes. Transplantation may provide a survival benefit over dialysis even for obese patients.
This document contains a bibliography divided into sections on basic science, oncology, prognosis, burden of illness, and HIV. It lists over 100 references for studies that have used bioelectrical impedance analysis to study body composition, fluid status, and the relationship between impedance measurements and health outcomes in various patient populations.
Introduction: Adjuvant chemotherapy such as S-I is thought to prolong the life expectancy of patients with gastric cancer. The
number of older patients with gastric cancer has recently been increasing. Here we examined the prognosis of older patients with stage II or III gastric cancer.
Methods: The study cohort comprises 658 patients with stage II or III gastric cancer who underwent curative surgery from 1994 to 2014 in our institution. From 1994 to 2003 was considered the early phase, whereas from 2004 to 2014 was considered the late phase. The patients were classifi ed by age into under 65 years (Non-Elderly [NE]); 65-74 years (Early Elderly [EE]); and over 74 years (Late Elderly [LE] groups.
1. The document discusses Valentin Fuster's disclosure information and level of involvement as chair of BG Medicine. It then covers several topics related to atrial fibrillation (AF) and antithrombotic treatment including Virchow's triad, different disease compartments, bleeding risks, and new directions in treatment.
2. Several studies and trials are summarized related to anticoagulation therapy for AF, risks of bleeding, outcomes for different antithrombotic regimens, and prevalence and management of AF in clinical practice based on various surveys.
3. The document provides an overview of Valentin Fuster's disclosure statement and then reviews the literature on antithrombotic treatment and
Role of the Biochemistry Labs in Promoting the Health Care Services for the I...IJERA Editor
The health care in the State of Kuwait depends to a greater extent on the biochemical and clinical labs attached
at each hospital. The data obtained from these laboratories will facilitate the process of diagnosing the disease
accurately. This will have a positive impact on the selection of appropriate treatment for the patients in general
and for diabetics specifically.
The main objective of this research was to build a profile for lab analysis and a database for building a
comprehensive system of integrated activities to raise health care for diabetic patients in Kuwait. The study
revealed the burden of admitted diabetic cases on the blood chemistry laboratory in Sabah Hospital (in relation
to length of stay and total numbers of lab requests). The aim was fulfilled by designing a model of the
biochemical tests for diabetics; filling in forms from the reality of patient data, completing and analyzing the
results electronically.
The study showed the importance of biochemical and clinical labs since they act as the link of patient's
information at the secondary health care level.
El documento habla sobre Charles Darwin y su teoría de la evolución de las especies. Explica que Darwin llegó a la conclusión de que las especies se originan a partir de una especie ancestral a través de un proceso de selección natural. Aunque sus ideas evolutivas revolucionarias no fueron bien recibidas inicialmente, hoy constituyen la base del neodarwinismo, la teoría más aceptada para explicar el origen y la evolución de las especies. El documento también anuncia una exposición sobre Darwin que se llevará a cabo en
The document is a newsletter from the IWA Specialist Group on Wetland Systems for Water Pollution Control dated June 2014. It provides information on:
- Recent membership trends which show membership between 450-550 and is well distributed globally.
- Updates to the group's constitution to standardize the conference proposal process and implement electronic voting for future conference sites.
- An upcoming election for new Regional Coordinators according to the new constitution.
- A proposal for a new IWA Task Group on "Mainstreaming the use of treatment wetlands".
- Upcoming events for the group including their biennial conference in Shanghai in October 2014.
Role of ayurveda in the management of cancerDr Joban
this pdf contains a compilation of various presentations and papers to get an idea how Ayurved -Panchakarma- Herbal treatment can be helpful to combat Cancer, chemotherapy, Radio therapy hazards, antitumor activities of plants, role of Ayurveda diet in prevention of cancer
Robert C. Shepard has extensive experience in cancer research and clinical oncology spanning over 40 years. He received his MD from Duke University and has held academic and clinical positions at several prestigious institutions. Currently, he works as a consultant in oncology drug development and clinical trials. He has led numerous clinical trials for both pharmaceutical and biotech companies and has published extensively in peer-reviewed journals. His expertise includes all phases of clinical trial design and implementation.
This document discusses the need for improved evidence-based searching capabilities at the intersection of genetics and human genome variation research. It notes that while genetics and clinical evidence sources exist separately, the integration of the two fields is lacking. It then surveys some current tools that provide an interface for searching genetics and evidence-based medicine, but suggests more specialized resources are still needed. The document concludes by proposing further developments like centralized test registries and technologies to map genomic data to clinical pathways based on evidence-based standards.
This curriculum vitae outlines the education and career of Dr. Edgar Lichstein, including his medical training, residencies, fellowships, military service, licenses, appointments, memberships, awards, grants, presentations, and publications. It details his roles as a professor, researcher, and leader in departments of medicine and cardiology over his 50+ year career at institutions including NYU, SUNY, and Maimonides Medical Center.
A cross-sectional study on the prevalence of cardiovascular risk factors amon...Jameel Hijazeen
YouTube Video of me presentation these results: http://www.youtube.com/watch?v=YocIOa-5eI8
By Jameel Khaleel Hijazeen (1); Oday Zayid Al-Ma'aitah (1); Mahmoud Yaseen Abuznaid, MD (2); Ahmed Nader Abo.sharak (1); Khaled Ali AlShar' (1); Imad Farjou, MD, PhD (3).
[1] Sixth-year medical students, Faculty of Medicine, Mu'tah University, Karak, Jordan.
[2] Intern, Al-Bashir Teaching Hospital, Amman, Jordan.
[3] Department of Pharmacology, Faculty of Medicine, Mu'tah University, Karak, Jordan.
طلاب السنة السادسة: جميل خليل حجازين، عدي زايد المعايطة ، احمد نادر ابوشرخ، خالد علي الشرع.
طبيب إمتياز، مستشفى البشير: محمود ياسين أبوزنيد.
الأستاذ المشرف: عماد فرجو.
----------------------------------------------------------------
It was presented by me, Jameel Khaleel Hijazeen, sixth-year medical student at Mu'tah University, today, April 11th, 2013, at the 9th Scientific Conference of the Faculty of Medicine at Mu'tah University, Karak, Jordan.
There is always something better! Especially when you are doing something you never did before. Therefore, any feedback is more than welcome.
Some photos and more details about this research and the conference: http://amanfrommoab.com/2013/04/11/the-ninth-scientific-conference-of-the-faculty-of-medicine-at-mutah-university-karak-jordan-april-3-4-2013-2/
This document summarizes the implications of COVID-19 for preventing and treating thrombotic complications. It was endorsed by several thrombosis societies and signed by over 60 experts. The key points are:
1) COVID-19 infection is associated with a prothrombotic state and increased risk of thrombotic complications including pulmonary embolism, deep vein thrombosis, ischemic strokes and arterial thromboses.
2) Clinicians should consider prophylactic anticoagulation for hospitalized COVID-19 patients, especially those with elevated D-dimer or inflammatory markers or who are immobilized.
3) Patients with confirmed VTE or arterial events should receive full anticoagulation treatment. Long-term
The document summarizes a study that aimed to predict clinical failure in patients with metastatic prostate cancer by identifying genes related to prostate cancer. Researchers analyzed gene expression levels of androgen receptor, estrogen receptor, and stem cell markers in cancer and stromal cells collected via laser capture microdissection from biopsy samples of 76 patients. Logistic regression analysis showed that expression of Sox2, Her2, and CRP in cancer cells and AR and ER in stromal cells highly predicted prostate-specific antigen recurrence. Ten factors were identified as prognostic for cancer-specific survival, including expression of Oct1, TRIM36, Sox2, c-Myc, AR, Klf4, ER, and clinical parameters. Patients were divided into risk
cancer becoming major death reason throughout the world. modern medicne is not upto mark in treating cancer because of drug resistance and many side effects. there is necessary for multi target drug therapy with less side efffects which can be only possible through ayurveda through proper research. we have identified multi target drug therapy either by single plant derivatives or by combination of synergistic plant derivatives to target different pathways of cancer cell progression at a time. tinosporin berberibe , curcumin, ellagic acid , and other derivatives derived from same herbs like essential oil, bhasma of same herb and other derivatives combined together in dose dependent ratio has shown good activity against cancer cell progression and survival
This document discusses using proteomics and metabolomics techniques to identify biomarkers for early detection of Amyotrophic Lateral Sclerosis (ALS). It describes previous proteomics studies that identified three biomarkers in CSF and interest in cystatin C as a diagnostic biomarker. Metabolomics studies using NMR on CSF have also found 17 relevant metabolites and perturbations in glucose metabolism. The conclusion is that proteomics and metabolomics show promise as techniques for early ALS detection but require further validation studies.
This curriculum vitae summarizes the career and qualifications of Joseph P. Hanna M.D. It details his employment history including roles at MetroHealth Medical Center and Case Western Reserve University. It also lists his appointments, licensure, education, research funding, publications, professional affiliations and committees. Dr. Hanna is currently an Associate Professor at Case Western Reserve University specializing in neurology with a focus on stroke.
This document summarizes a study that aimed to identify subtypes of type 2 diabetes (T2D) based on clinical characteristics before diagnosis and determine if genetic risk factors differ between the subtypes. The study used clustering analysis to group 832 T2D cases into two clusters based on metabolic and anthropometric measurements. Cox proportional hazards models were then used to test if T2D genetic risk factors differed between the clusters. The clustering resulted in two clusters with cluster one having a higher percentage of women and higher values for waist-to-hip ratio, HDL, and fasting insulin. No statistically significant differences were found in genetic risk factors between the clusters, though adiposity genes were most associated with T2D risk, suggesting an interaction
This curriculum vitae summarizes the career and qualifications of Dr. Emad Aziz, an Associate Professor of Medicine at Mount Sinai specializing in cardiac electrophysiology. It details his medical training and education in Egypt and the United States, including fellowships in cardiology and electrophysiology. It also lists his professional experience, teaching responsibilities, licenses, certifications, publications, and professional society memberships.
This curriculum vitae outlines the educational qualifications and professional experience of Saeed Saeed Alghamdi. He holds a PhD in Toxicology from the University of London and has over 20 years of experience working as a professor of Pharmacology and Toxicology. He has extensive research experience studying the toxic effects of organic solvents and heavy metals. He has published several articles and books on topics related to toxicology.
Obesity in CKD and Renal Transplantation 2017Meguid Nahas
This document discusses obesity and chronic kidney disease (CKD). It notes that obesity is associated with an increased risk of CKD and accelerated progression of CKD. While weight loss is generally recommended for obese patients with CKD, forced weight loss on dialysis can be harmful and is not associated with improved post-transplant outcomes. Transplantation may provide a survival benefit over dialysis even for obese patients.
This document contains a bibliography divided into sections on basic science, oncology, prognosis, burden of illness, and HIV. It lists over 100 references for studies that have used bioelectrical impedance analysis to study body composition, fluid status, and the relationship between impedance measurements and health outcomes in various patient populations.
Introduction: Adjuvant chemotherapy such as S-I is thought to prolong the life expectancy of patients with gastric cancer. The
number of older patients with gastric cancer has recently been increasing. Here we examined the prognosis of older patients with stage II or III gastric cancer.
Methods: The study cohort comprises 658 patients with stage II or III gastric cancer who underwent curative surgery from 1994 to 2014 in our institution. From 1994 to 2003 was considered the early phase, whereas from 2004 to 2014 was considered the late phase. The patients were classifi ed by age into under 65 years (Non-Elderly [NE]); 65-74 years (Early Elderly [EE]); and over 74 years (Late Elderly [LE] groups.
1. The document discusses Valentin Fuster's disclosure information and level of involvement as chair of BG Medicine. It then covers several topics related to atrial fibrillation (AF) and antithrombotic treatment including Virchow's triad, different disease compartments, bleeding risks, and new directions in treatment.
2. Several studies and trials are summarized related to anticoagulation therapy for AF, risks of bleeding, outcomes for different antithrombotic regimens, and prevalence and management of AF in clinical practice based on various surveys.
3. The document provides an overview of Valentin Fuster's disclosure statement and then reviews the literature on antithrombotic treatment and
Role of the Biochemistry Labs in Promoting the Health Care Services for the I...IJERA Editor
The health care in the State of Kuwait depends to a greater extent on the biochemical and clinical labs attached
at each hospital. The data obtained from these laboratories will facilitate the process of diagnosing the disease
accurately. This will have a positive impact on the selection of appropriate treatment for the patients in general
and for diabetics specifically.
The main objective of this research was to build a profile for lab analysis and a database for building a
comprehensive system of integrated activities to raise health care for diabetic patients in Kuwait. The study
revealed the burden of admitted diabetic cases on the blood chemistry laboratory in Sabah Hospital (in relation
to length of stay and total numbers of lab requests). The aim was fulfilled by designing a model of the
biochemical tests for diabetics; filling in forms from the reality of patient data, completing and analyzing the
results electronically.
The study showed the importance of biochemical and clinical labs since they act as the link of patient's
information at the secondary health care level.
El documento habla sobre Charles Darwin y su teoría de la evolución de las especies. Explica que Darwin llegó a la conclusión de que las especies se originan a partir de una especie ancestral a través de un proceso de selección natural. Aunque sus ideas evolutivas revolucionarias no fueron bien recibidas inicialmente, hoy constituyen la base del neodarwinismo, la teoría más aceptada para explicar el origen y la evolución de las especies. El documento también anuncia una exposición sobre Darwin que se llevará a cabo en
The document is a newsletter from the IWA Specialist Group on Wetland Systems for Water Pollution Control dated June 2014. It provides information on:
- Recent membership trends which show membership between 450-550 and is well distributed globally.
- Updates to the group's constitution to standardize the conference proposal process and implement electronic voting for future conference sites.
- An upcoming election for new Regional Coordinators according to the new constitution.
- A proposal for a new IWA Task Group on "Mainstreaming the use of treatment wetlands".
- Upcoming events for the group including their biennial conference in Shanghai in October 2014.
El documento habla sobre las protestas recientes de maestros de la Coordinadora Nacional de Trabajadores de la Educación (CNTE) contra la reforma educativa en México. Los maestros bloquearon el acceso al Congreso para impedir la aprobación de leyes secundarias de la reforma. Hubo actos de violencia durante las protestas, aunque los maestros niegan su responsabilidad y afirman que fueron provocados por personas infiltradas. El día de hoy, los maestros continúan bloqueando los accesos al Congreso.
Este documento trata sobre el mantenimiento industrial. Explica los diferentes tipos de mantenimiento como el correctivo, preventivo, predictivo y de mantenimiento productivo total. También describe conceptos clave como la fiabilidad, mantenibilidad y disponibilidad. Finalmente, cubre temas como la planificación del mantenimiento industrial y métodos de control del estado como la monitorización de vibraciones y temperatura para la detección de fallas.
Este documento presenta una lista de 8 categorías estadísticas sobre las provincias españolas: 1) las más envejecidas, 2) las más jóvenes, 3) las con más parados, 4) las que más exportan, 5) las donde se conceden más hipotecas, 6) las con más afiliados a la Seguridad Social, 7) las que más dinero gastan, y 8) las que más dinero ingresan. Para cada categoría, se indica la fuente de datos y el año de la información estadística.
El currículum vitae presenta los datos personales y la educación de Johanna Lizbeth Sánchez Samayoa, quien estudió contaduría en el Instituto Nacional Texistepeque y la Escuela José Alejandro Cabrera. Realizó prácticas como auxiliar contable en un despacho y una mueblería, donde obtuvo referencias laborales de sus jefes. También proporciona referencias personales.
The pH Conductivity Meters are multi parameter micro processor based highly accurate pH and conductivity meters these type of meters are best when, more than one parameter in the given solution require to be checked and recorded.For More Information Please Logon http://goo.gl/VEvLke
El documento define el turismo cultural como aquel relacionado con el patrimonio y las culturas tradicionales como monumentos y sitios histórico-artísticos. También señala que los turistas ahora exigen mayor calidad de servicios y eligen destinos que preserven el medio ambiente y la cultura local. Además, describe el turismo urbano en Buenos Aires, destacando su patrimonio histórico, diversidad cultural y status como capital cultural de Latinoamérica.
Este documento describe las aplicaciones para crear y difundir contenidos en línea como páginas web, blogs y wikis. Estas herramientas permiten alojar, gestionar y compartir contenidos y posibilitan la comunicación bidireccional. Se definen principalmente por su capacidad de creación y edición de contenido, su relación con la World Wide Web y el grado de participación que permiten.
Este documento clasifica tres tipos principales de animales: 1) los vertebrados, que tienen huesos, 2) los carnívoros, que comen carne, y 3) los invertebrados, que no tienen huesos y se arrastran.
Google Analytics Konferenz 2016: Dashboards mit Google Analytics und Excel me...e-dialog GmbH
Wie Dashboards mit den Analytics Boardmitteln eingerichtet werden können und darüberhinaus in MS Excel durch Plugins automatiisert (und gepimpt) werden können.
Habitação colectiva na áfrica lusófona – análise de dois casos de estudoLara Plácido
1) O documento discute a arquitetura moderna e habitação coletiva na África Lusófona, com foco em Angola e Moçambique.
2) A arquitetura moderna começou a se desenvolver nessas regiões nas décadas de 1940-1970, impulsionada pelo desenvolvimento colonial e ideias do Movimento Moderno. Arquitetos como Vasco Vieira da Costa projetaram habitações que se adaptavam ao clima quente e úmido.
3) Dois casos de estudo são analisados: um edifício
Indo-Japan Trade and Investment Highlights:
India and Japan to work IT together
Japanese firm Looking to Strengthen Aviation Defence Presence in India
Omori to Acquire Majority Stake in Multi Pack Systems
Return of Mazda in India
Currency Swap to Control Falling Rupee and Improving Financial Ties with Japan
Suzuki to make India Hub for Export of Left Wheel Drive Swift Models to other Emerging Markets
India and Japan Launch Joint Research Programs in Applied Science
The Anime Bond
Knowledge Center: Overview of Indian Labour Law
El documento describe la infraestructura y servicios que ofrece CEDIA para conectividad, repositorios, proyectos, capacitación, colaboración y eventos. Incluye la Red Avanzada de CEDIA, Internet, Eduroam, federaciones, intercambio VoIP, oficina virtual, clúster, nube, grabación de eventos, campus virtual, entre otros. El objetivo es apoyar la investigación, enseñanza y colaboración entre instituciones miembros.
Este documento proporciona un directorio de descuentos para rubros como automóvil, hogar y familia en Mexicali, Baja California. Incluye más de 50 negocios con sus nombres, actividades, direcciones, teléfonos y los porcentajes de descuento que ofrecen, los cuales van del 10% al 50% dependiendo del negocio y servicio.
This document provides an overview of the elementary curriculum for grades 3-5 at Yeil Christian International School in South Korea. It outlines the core subjects of reading, English/language arts, math, science, and social studies. For third grade, the curriculum focuses on developing reading fluency and comprehension, grammar, spelling, and writing skills. Students will read from the Not So Very Long Ago textbook series and the English 3 textbook. The curriculum integrates fundamentalist Christian views and aims to encourage biblical worldviews, though these views may not reflect all students, faculty or administration.
This document discusses semantic analysis and natural language processing. It describes 7 typical tasks: 1) topic detection, 2) named entity recognition, 3) co-reference resolution and word sense disambiguation, 4) relation extraction, 5) sentiment analysis, 6) social annotation, and 7) text summarization. For each task it provides details on the goal, common techniques used, and examples. The document also discusses publishing content as linked data using semantic vocabularies and ontologies to make it machine-readable and processable.
This curriculum vitae outlines the education and career of Dr. Jeffrey C. Fink. It details his education, including degrees from Clark University and Case Western Reserve University School of Medicine. It provides a comprehensive history of his academic appointments and certifications, clinical and research activities, teaching experience, grant support, and publications. Dr. Fink currently serves as Professor of Medicine and Epidemiology and Chief of General Internal Medicine at the University of Maryland School of Medicine.
This curriculum vitae summarizes the professional experience and qualifications of Dr. John C. Ruckdeschel. He has over 40 years of experience in oncology, including serving as CEO of several major cancer centers. His educational background includes an MD from Albany Medical College and further training at NIH. He has held professorships at multiple universities and has received many honors for his contributions to oncology.
Andrew Ghio is a medical officer at the EPA. He received his MD from Boston University School of Medicine in 1981 and has had a long career in medicine, including positions at Duke University and UNC. He is board certified in internal medicine, pulmonary medicine, and occupational medicine. His CV details his education, training, appointments, certifications, publications, and professional affiliations.
Dr. John Catanzaro is a naturopathic physician specializing in integrative oncology and personalized medicine. He received his ND from Bastyr University and has additional certifications in genetics and theology. He has owned several wellness clinics and founded non-profits focused on cancer research. Currently, he works as a physician consultant providing functional genetics testing and counseling.
This document is a curriculum vitae for Dr. Aria F. Olumi. It summarizes her education, including degrees in chemistry and medicine from UC San Diego and USC. It details her medical training in surgery and urologic surgery. It also outlines her faculty appointments at Harvard Medical School and administrative roles at various hospitals. Finally, it lists publications, honors, committee service, and history of funded research projects in areas like prostate cancer and bladder dysfunction related to diabetes.
This document provides a curriculum vitae and bibliography for Antonio Sergio Torloni, MD. It details his present position as Medical Director of Transfusion Medicine at Banner MD Anderson Cancer Center. It also lists his previous academic ranks and positions at Mayo Clinic from 2004-2013. His education includes an MD from University of Brasilia in 1980 and residencies in pathology and pediatrics. He has over 30 years of experience in transfusion medicine, apheresis, and stem cell collection.
Northwestern University Feinberg School of Medicine, Department of
Anesthesiology, 1984–1988
Northwestern University Feinberg School of Medicine, Department of
Anesthesiology, 1988–1995
Northwestern University Feinberg School of Medicine, Department of
Anesthesiology, 1995–2003
Associate:
Northwestern University Feinberg School of Medicine, Department of
Anesthesiology, 2003–2009
Professor:
Northwestern University Feinberg School of Medicine, Department of
Anesthesiology, 2009–present
Lectures:
Northwestern University Feinberg School of Medicine, Department of
Anesthesiology, 1984–present:
My board certifications are in Neurology, Biochemical Genetics, and Molecular Genetics. After selling my molecular and biochemical diagnostics company in 2015, I have been focused on peer reviewed publications and advancing the field of Precision Medicine.
South Africa has a robust health science research sector across universities, government agencies, and private organizations. Key areas of focus include infectious diseases like HIV/AIDS, prevalent cancers, genetic disorders, and clinical trials. Major research infrastructure includes DNA sequencing facilities, biotechnology centers, and programs developing drugs from indigenous plants. South Africa has competitive advantages in health research due to high disease incidence and population diversity. Funding comes from government agencies, international partnerships, private trusts, and more.
This curriculum vitae provides biographical and professional information about Dr. Aalap C. Shah, an anesthesiologist. It details his education, including undergraduate and medical degrees from Johns Hopkins University and the University of Pittsburgh. It outlines his residency training in anesthesiology at the University of Washington and clinical and research fellowships at Boston Children's Hospital. It also lists his current appointments, certifications, publications, teaching experience, and involvement in quality improvement initiatives and global health work.
38 experts on bpa panel consensus statement. effects in animals and potential...ricguer
Un conjunto de 38 prestigiados científicos de todo el mundo alertan sobre el potencial nocivo y los impactos de exposición al Bisphenol A para la salud humana.
This document provides a summary of Yuling Chi's background and qualifications. It summarizes that she has over 20 years of experience in biochemistry, enzymology, molecular biology and other fields. She has directed a research laboratory for 7 years, overseeing projects, trainees, and publishing papers. Her research has focused on lipid and carbohydrate metabolism, and the identification of drug candidates for conditions like hypertension, obesity and diabetes.
This document is a curriculum vitae for Michael S. Lauer, MD, FACC, FAHA that provides biographical information over 10 pages. It includes his education, training, appointments, awards, research interests, teaching experience, and publications. He received his BS summa cum laude from Rensselaer Polytechnic Institute in 1983 and MD magna cum laude from Albany Medical College in 1985. He has held leadership positions at the Cleveland Clinic Foundation and currently serves as the Director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute.
This document is the curriculum vitae of Dr. Michael S. Lauer, which provides biographical and professional details over 6 pages. It includes his education history, postdoctoral training, licensure, appointments, awards, memberships, and publications. Currently, Dr. Lauer is the Director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute at the NIH in Bethesda, Maryland, overseeing over 120 staff and a $1.5 billion research portfolio.
The document summarizes a Sino-American symposium on clinical and translational research held in Beijing, China from June 16-18, 2010. The symposium was co-organized by the Chinese Academy of Medical Sciences, GlobalMD organization, and the US National Institutes of Health Clinical Center. It focused on building collaboration and communication between US and China in clinical and translational research. Over the three days, there were keynote speeches, panels, and sessions on various topics in global health research, infectious diseases, bioethics, and more. The goal was to foster US-China collaboration in research, education, innovation, and improving global healthcare.
Walter F. Boron, Emile L. Boulpaep - Medical Physiology (2017, Elsevier) - li...RicardoPessoa40
This document provides information about the third edition of the textbook "Medical Physiology" edited by Walter F. Boron and Emile L. Boulpaep. It lists the editors and over 30 contributors to the textbook. The preface discusses updates that have been made to the third edition, including revisions to many chapters to reflect new molecular insights and physiological concepts. Over 190 tables and figures were updated or added, along with an increase in supplemental online notes. The editors aim to integrate concepts from molecular to human physiology and place physiology in a clinical context.
This document is a curriculum vitae for Dr. Michael S. Lauer that provides biographical information over 10 pages. It includes his education history, postdoctoral training, licensure and certifications, appointments, awards and honors, memberships, research interests, teaching experience, and publications. He is currently the Director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute at the NIH in Bethesda, Maryland. The CV demonstrates an accomplished career in cardiology, epidemiology, and biomedical research leadership.
Pathologists have made significant contributions to medicine, including many Nobel Prize-winning discoveries. Pathology training in the US and Canada involves 3-4 years of residency, and pathologists can specialize in areas like anatomical pathology, clinical pathology, and various subspecialties. Pathologists work in various settings like community hospitals, medical schools, government agencies, and private companies.
The document summarizes information about the Vermont Lung Center (VLC) located at the University of Vermont. It provides details about the VLC's history, current research areas, funding sources, and accomplishments over time. The VLC started as an NIH-funded center in the 1970s and currently receives funding from NIH and other sources like the Cystic Fibrosis Foundation. Its research focuses on areas like epithelial cell signaling, pulmonary immunity, and clinical trials for conditions such as asthma and cystic fibrosis. The VLC has grown significantly since 2000 and has had success obtaining grants and publishing research.
Adrian L. Winters III has over 30 years of experience in pathology laboratories. He has worked as a pathologists' assistant, medical technologist, and research assistant. His experience includes positions at hospitals in Texas, Oklahoma, Oregon, Arizona, and Missouri. He maintains certifications as a pathologists' assistant, medical technologist, and Reiki master practitioner. Winters has authored publications on cancer research and presented on complementary medicine. He received a PhD in Integrative and Complementary Medicine and holds an MS in Microbiology and Immunology.
1. HKA 1
CURRICULUM VITÆ
Date Prepared: April 21, 2015
Name: Hava Karsenty Avraham, Ph.D
Office Address: Northeastern University
Center for Drug Discovery
116 Mugar Hall
360 Huntington Avenue
Boston, MA 02115
Home Address: 22 Heath Hill Road
Brookline, MA 02445
Work Phone: 617-373-4218
Cell Phone: 617-775-0697
Work E-mail: h.avraham@neu.edu
Private email: havraham2007@gmail.com
EDUCATION
1977 B.S. Biology, High Honors Science Faculty Hebrew
University Jerusalem, Israel
1982 Ph.D. General & Tumor
Immunology, High
Honors
Hebrew University,
Jerusalem, Israel
POSTDOCTORAL TRAINING
1982-1985 Postdoctoral Fellow Molecular Biology and
Immunology
Weizmann Institute of
Science, Rehovot, Israel
1985-1988 Postdoctoral Fellow Molecular Biology Whitehead Institute,
Massachusetts Institute of
Technology, Cambridge,
MA
FACULTY ACADEMIC APPOINTMENTS
1982 Senior Assistant Microbiology and Basic
Immunology
The Hebrew University,
Jerusalem, Israel
2. HKA 2
1989-1990 Instructor Medicine Harvard Medical School,
Boston, MA
1991-1995 Assistant Professor Medicine Harvard Medical School,
Boston, MA
1995-2014 Associate Professor Medicine Harvard Medical School,
Boston, MA
2014-Present Adjunct Professor Biology Northeastern University,
Center for Drug
Discovery, Boston, MA
APPOINTMENTS AT HOSPITAL/AFFILIATED INSTITUTIONS
1989-1989 Scientific Associate Medicine, Division of
Experimental Medicine
New England Deaconess
Hospital, Boston, MA
1989-1996 Senior Scientist Hematology/Oncology New England Deaconess
Hospital, Boston, MA
1996-7/2014 Senior Scientist Hematology/Oncology Beth Israel Deaconess
Medical Center, Boston,
MA
1/2011-7/2014 Principal Faculty Stem Cell Research Harvard Stem Cell
Institute, Cambridge, MA
MAJOR ADMINISTRATIVE LEADERSHIP POSITIONS
2001-7/2005 Associate Chief Experimental Medicine Beth Israel Deaconess
Medical Center, Boston,
MA
11/2007-7/2014 Associate Chief Experimental Medicine Beth Israel Deaconess
Medical Center, Boston,
MA
COMMITTEE SERVICE
Local
1990-Present Masters and Doctoral Theses
Committee, Biological Sciences
Harvard Medical School
1990-2014 Member
National
2003-2005 Research Committee on
Scientific Sessions Program
American Heart Association
2003-2005 Member
3. HKA 3
2014-Present U54 Program Steering
Committee
University of California, San Diego
Moores Cancer Center
2014-Present Member
PROFESSIONAL SOCIETIES
1990- American Society of Hematology
1990-Present Member
1993- American Society of Hematology
1993-Present Member
1997- American Association for
Cancer Research (AACR)
1997-Present Member
2002- International Society for Stem Cell Research
2002-Present Member
GRANT REVIEW ACTIVITIES
1996 Medical Biochemistry Study
Section
National Institutes of Health
1996 Reviewer
1996 Hematology Study Section National Institutes of Health
1996 Reviewer
1997-1998 Hematopoiesis Research &
Development
U.S. Department of Veterans Affairs
1997-1998 Reviewer
1999 Hematology Study Section National Institutes of Health
1999 Reviewer
1999-2002 National Molecular Signaling
Committee
American Heart Association
1999-2002 Reviewer
2000-2003 Cell Biology, Breast Research
Program
U.S. Army Medical Research and
Materiel Command/Congressionally
Directed Medical Research Programs
2000-2003 Reviewer
2002 Basic & Clinical National
Cancer Institute Initial Review
Group
National Institutes of Health
2002 Reviewer
2003 Hematology Subcommittee 1
(HEM-1)
National Institutes of Health
2003 Reviewer
2003-2005 Hemostasis and Thrombosis
Study Section (HT)
National Institutes of Health
2003-2005 Reviewer
2004 Basic and Preclinical Studies,
Subcommittee C
National Cancer Institute
4. HKA 4
2004 Reviewer
2004 Neurogenesis and Cell Fate
Study Section
National Institutes of Health
2004 Reviewer
2004 Stem Cells in Aging National Institutes of Health
2004 Reviewer
2004 Cancer Research Fellowship
Study Section, Oncological
Science
National Institutes of Health
2004 Reviewer
2004 Physical and Engineering
Sciences Grant Committee
National Science Foundation (NSF)
2004 Reviewer
2004-2005 Lung and Blood Institute
(NHLBI) Program
National Institutes of Health
2004-2005 Reviewer
2005 3rd
Annual Meeting of the
International Society for Stem
Cell Research
International Society for Stem Cell
Research
2005 Reviewer
2005 Centers of Biomedical Research
Excellence Review Panel
National Institutes of Health
2005 Reviewer
2005 Grant Committee International Society for Stem Cell
Research
2005 Reviewer
2008 Hematopoiesis Special
Emphasis Panel, ZRG1 HEME-
D (NHLBI)
National Institutes of Health
2008 Reviewer
2008 Translational Breast Cancer
Research Grant Committee
American Association for Cancer
Research (AACR)
2008 Reviewer
2009 Grant Committee California Breast Cancer Research
Program
2009 Reviewer
2009 RFA OD-09-003 Challenge
Grant Panel 6
National Institutes of Health
2009 Reviewer
2009 Molecular Oncogenesis
(MONC) Study Section
National Institutes of Health
2009 Reviewer
2010-2012 Grants Committee United States—Israel Binational Science
Foundation (BSF)
2010-2012 Reviewer
5. HKA 5
2010 Systems Biology Committee Netherlands Genomic Initiative
2010 Reviewer
2010 CCNE Special Emphasis Panel,
Nanotechnology
National Institutes of Health
2010 Reviewer
2010 Review Panel 6.5 Academy of Finland, Cancer Research
2010 Reviewer
2010 Tumor Biology Panel California Brest Cancer Research
Program
2010 Reviewer
2010 Grants Committee Cancer Research UK
2010 Reviewer
2010 Grants Committee, Stem Cells Israel-Japan Scientific Research
Cooperation
2010 Reviewer
2011-2013 Grants Reviewer Florida Department of Health, Bankhead
Coley Cancer Research Program
2011-2013 Reviewer
2011 Tumor Biology Panel California Breast Cancer Research
Program
2011 Reviewer
2011 Cancer Health Disparities and
Diversity in Basic Cancer
Research Panel (ZRG1 OBT-A)
National Institutes of Health/National
Cancer Institute
2011 Reviewer
2011-2012 Grants Committee Italian Ministry of Health, Department of
Public Health and Innovation
2011-2012 Reviewer
2013 Grants Committee Center for the Advancement of Science
in Space (CASIS)
2013 Reviewer
EDITORIAL ACTIVITIES
Ad hoc Reviewer
American Journal of Pathology
Journal of Biochemistry
Journal of Biological Chemistry
Breast Cancer Research
British Journal of Haematology
Cancer Research
Clinical Medicine Insights: Therapeutics
Gene Regulation and Systems Biology
Journal of Immunology
Journal of Clinical Investigation
Libertas Academica
Molecular Biology of the Cell
6. HKA 6
Other Editorial Roles
1997-2002 Editorial Board Member Blood
2009-2011 Editor-in-Chief Journal of Breast Cancer: Targets
and Therapy
2011-2014 Editorial Board Member ISRN Biochemistry
2011-2013 Associate Editor PLoS ONE
HONORS AND PRIZES
1983-1984 Israel Cancer
Research Fellowship
Cancer Research
Foundation
1984 Leah and Dr. Arthur
Felix Academic
Achievement Award
Hebrew University
Jerusalem, Israel
Excellence in academic
achievement
1985 Fulbright-Hays
Faculty Research
Abroad Fellowship
U.S. Department of
Education
1986-1988 Rothschild
Fellowship
Yad Hanadiv
Foundation, Israel
Fellowship to help young
scholars of outstanding
academic merit and
potential to advance in
their respective fields
1991 William F. Milton
Fund
Harvard Medical School Supports research
conducted by Harvard
University Faculty
2000-2001 Breast Cancer
Research Program
Postdoctoral
Fellowship Award
U.S. Department of
Defense
Supports the training of
exceptionally talented
doctoral or medical
graduates
1999-2002 National Established
Investigator Award
American Heart
Association
Supports mid-career
investigators with unusual
promise and an
established record of
accomplishments
2003-2005 Career Enhancement
Award for Stem Cell
Research (K18)
National Institutes of
Health
Encourages investigators
to obtain the training and
career development they
need to appropriately use
stem cells in their
research
REPORT ON FUNDED PROJECTS
Costs given are per year amounts.
1992-1997 Hematopoiesis and Megakaryocytopoiesis
Genentech, Inc.
7. HKA 7
Co-PI (Total direct costs/5 years shared between 2 co-PIs)
1994-1999 Studies of a Novel Tyrosine Kinase in Megakaryocytes
NIH - 1R01 HL51456
PI (Direct: $202,124, Indirect: $146.539, Total: $348,663)
1996-2001 Studies of a Related Adhesion Kinase in Megakaryocytes
NIH - 1R01 HL55445
Co-PI (Direct: $204,436, Indirect: $148,216, Total: $352,652)
1998-2001 Regulation of ErbB-2 and Src Signaling by CHK and Csk Tyrosine
Kinases in Breast Cancer
U.S. Department of Defense - BC972668
PI (Direct: $65,305, Indirect: $48,325, Total: $113,630)
1998-2002 CHK: a Novel Signaling Molecule in Breast Cancer
NIH - 1R01 CA76226-01
PI (Direct: $162,653, Indirect: $120,363, Total: $283,016)
1999-2002 Studies of RAFTK Tyrosine Kinase in Platelets
American Heart Association - 9940133N
PI (Direct: $68,131, Indirect: $6,813, Total: $74,944)
1999-2002 Studies of Vascular Endothelial Growth Factor (VEGF) Signaling in Breast
Cancer Cells
U.S. Department of Defense – BC980169
PI (Direct: $70,000, Indirect: $49,000, Total: $119,000)
2000-2001 Role of BRCA1 in Sporadic Breast Cancer
Commonwealth of Massachusetts – Experienced Breast Cancer Grant
PI (Direct: $20,000, Indirect: $0, Total: $20,000)
2000-2001 Role of BRCA1 in Sporadic Breast Cancer
Milheim Foundation
PI (Direct: $17,100, Indirect: $0, Total: $17,100)
2000-2002 Regulation of BRCA1 Signaling and Function by Heregulin
NIH/NCI - 1R21 CA87290-0
PI (Direct: $75,000, Indirect: $48,125, Total: $123,125)
2001-2002 Regulation of BRCA1 function by AKT Kinase in Breast Cancer Cells
Massachusetts Department of Public Health
PI (Direct: $20,000, Indirect: $0, Total: $20,000)
2001-2002 Studies of CHK Kinase in Pancreatic Cancer Cells
Lustgarten Foundation, Inc.
PI (Direct: $100,000, Indirect: $25,000, Total: $125,000)
2002-2005 Effects of Csk Homologous Kinase Overexpression on HER2
U.S. Department of Defense
Co-PI (Direct: $50,000, Indirect: $35,000, Total: $85,000
2003-2005 Career Enhancement Award for Stem Cell Research
NIH - K18
PI (Direct: $250,000, Indirect: $175,000, Total: $425,000)
2003-2005 Role of CXCR4
Milheim Award for Excellence in Cancer Research, Milheim Foundation
Co-PI (Direct: $17,100, Indirect: $0, Total: $17,100)
2003-2004 Evaluation of CHK-Based Treatment in Brain Cancer
8. HKA 8
American Brain Tumor Society
Co-PI (Direct: $50,000, Indirect: $0, Total: $50,000)
2003-2010 Studies of a Novel BRCA1 Tricomplex in Breast Cancer
NIH - 1RO1 CA96805
PI (Direct: $225,000, Indirect: $157,500, Total: $382,500)
2004-2005 Targeting RNA Stabilization to Reduce Growth Factor Expression in
Breast Cancer Cells
U.S. Department of Defense – BC033037
PI (Direct: $75,000, Indirect: $52,500, Total: $127,500)
2004-2005 CD133 (AC133) as a Marker for Breast Cancer Stem Cells in Human
Breast Tumors
U.S. Department of Defense – BC033433
PI (Direct: $75,000, Indirect: $52,500, Total: $127,500)
2004-2005 The Role of Mammary Stem Cells in Neu/ErbB-2 Mediated
Carcinogenesis
U.S. Department of Defense – BC033433
PI (Direct: $75,000, Indirect: $52,500, Total: $127,500)
2004-2007 Program in Blood Coagulation and Vascular Biology
NIH/NHLBI – T32
Supervisor (PI: Elvis Tiburu)
2005 Summer Fellowship
Aid for Cancer Research
Supervisor (PI: Sunshine Dwojak)
2005 UICC Cancer Technology Transfer
Union for International Cancer Control (UICC)
Supervisor (PI: Anna Asenko)
2005-2006 Japan Foundation Fellowship
Japan Foundation
Supervisor (PI: Masayuki Sekine)
2005-2007 Studies on the Role of CHK Kinase in Neuroblastoma
Children’s Neuroblastoma Cancer Foundation
Co-PI (Direct: $25,000, Indirect: $0, Total: $25,000)
2006-2007 Detection of the Dynamics, Structure, and Orientation of the
Transmembrane Segment of ErbB2 in Model Membranes Using Solid-
State NMR Spectroscopy
U.S. Department of Defense
Supervisor (PI: Elvis Tiburu)
2008-2009 Cannabinoid Compounds Induce Hematopoietic Stem Cell Mobilization
National Blood Foundation
PI (Direct: $65,000, Indirect: $6,500, Total: $71,500)
2009-2010 Substance P Increases Breast Cancer metastasis to the Brain
U.S. Department of Defense – BC086391
Supervisor (PI: Shuxian Jiang)
2009-2010 Regulation of Breast Cancer Stem Cell Trafficking and Metastasis by Brain
Originated Signals
U.S. Department of Defense – BC086398
9. HKA 9
Supervisor (PI: Shuxian Jiang)
2009-2011 BRCA1 Sporadic Breast Cancer
NIH/NCI - 5R21 CA135226-02
PI (Direct: $88,000, Indirect: $61,600, Total: $149,600)
2010-2012 New Mechanisms for Breast Cancer Transmigration across the Blood Brain
Barrier
U.S. Department of Defense - BC094909, W81XWH-10-0648
PI (Direct: $183,718, Indirect: $135,032, Total: $318,750)
2011-2013 Oxidative Stress Increases the Blood-Brain Barrier Permeability, Resulting
in Increased Incidence of Brain Metastasis in BRCA Mutation Carriers
U.S. Department of Defense - BC102246, W91ZSQ0289N649
PI (Direct: $187,500, Indirect: $138,750, Total: $326,250)
REPORT OF LOCAL TEACHING AND TRAINING
No presentations listed below were sponsored by outside entities.
Local Invited Presentations
1988 The Rho Gene Family
Experimental Medicine, Deaconess Hospital
1992 Regulation of Megakaryocytopoiesis by Stem Cell Factor
Cellular and Molecular Biology Laboratory, Deaconess Hospital
1993 Molecular Studies of Megakaryocytopoiesis
Hematology/Oncology, Dana-Farber/Deaconess Hospital
1994-1998 Basic Science Teaching Conference
Hematology/Oncology, Deaconess Hospital
1999 Cancer Biology Seminar Series / Grand Rounds, Oncology
Immunology, Orthopedics, Neurology, Radiology, Deaconess Hospital
2002 Cancer Biology Seminar
Hematology/Oncology, Beth Israel Deaconess Medical Center
2003-2004 Vascular Biology
Hematology, Beth Israel Deaconess Medical Center/Harvard Medical School
2006 Vascular Biology
Hematology, Beth Israel Deaconess Medical Center/Harvard Medical School
2006 Vascular Biology
Biochemistry, Boston University School of Medicine
2007 Vascular Biology
Center for Drug Discovery, Northeastern University
2007 The Endocannabinoid System in Stem Cells
Center for Drug Discovery, Northeastern University
2008 The Role of the Endocannabinoid System in Bone Marrow Recovery following
Irradiation
Center for Drug Discovery, Northeastern University
2009 Vascular Biology
Hematology/Bone Marrow Transplant, Beth Israel Deaconess Medical Center
2009 The Protective effects of the CB2 Cannabinoid Agonists and the
Endocannabinoids on HIV-1 Gp120 Mediated Damage on Neural Progenitor Cells
10. HKA 10
Using in vitro and in vivo Studies
Center for Drug Discovery, Northeastern University
2009 Protective Effects of Cannabinoids on Substance P and HIV-1 Gp120 Mediated
Insult to the Blood Brain Barrier and Neural Progenitor Cells
Pharmacology & Experimental Therapeutics, Boston University School of
Medicine
2010 Pharmacologic Intervention in Inflammatory Responses: Inflammation and Breast
Cancer
Pharmacology & Experimental Therapeutics, Boston University School of
Medicine
2010 Approaches for Drug Discovery in Breast Cancer Metastasis in the Brain
Bouvé College of Health Sciences, School of Pharmacy, Northeastern University
2010 Cannabinoids and Stem Cell Research
Center for Drug Discovery, Northeastern University
2010-2012 Oncopharmacology
Pharmacology & Experimental Therapeutics, Boston University School of
Medicine
2011 Cannabinoid Modulation of the Blood-Brain Barrier Integrity in the Presence of
HIV Proteins
Center for Drug Discovery, Northeastern University
2011 Cancer Systems Biology: Tumor Dormancy
Center for Cancer Systems Biology, St. Elizabeth's Medical Center
2011 Substance P/NK-1R and VEGF/Angiopoietin-2 as Molecular Determinants in
Breast Cancer Metastasis to the Brain
2012 Alteration In COX-2 Signaling in Triple Negative (ER-/PR-/Her2) Breast Cancer
Cells and its Potential Application to Breast Cancer Disparity
Monthly Scientific Meeting, Dana-Farber Cancer Institute
2014 Cannabinoid Receptor Type2 Agonists Targeting Neurotoxicity and
Neuroinflamation in HIV-1 Mouse Model of HIV-Neurotoxicity
Center for Drug Discovery, Northeastern University
2014 CB2 Cannabinoid Receptor Agonists for the Treatment of HIV Associated
Neurological Disease (HAND)
Center for Drug Discovery, Northeastern University
Formally Supervised Trainees and Faculty
1989-1993 Sherry Chi, Ph.D. / Scientist, Genzyme, Cambridge, MA
1990-1993 Sally Cowley, Ph.D. / Head of James Martin Stem Cell Facility, School of
Pathology, Oxford University, U.K.
1991-1996 Naheed Banu, Ph.D. / Research Scientist II, Celgene, Summit, NJ
1991-2012 Yigong Fu, B.S.
1992-1996 Sandhya Raja, Ph.D. / Scientist, Biogen Idec, Cambridge, MA
1992-2013 Shuxian Jiang, B.S.
1993-1999 Roanna London, M.A. / Associate Director, Pfizer Research, Cambridge,
MA
1994-1999 Bijia Deng, Ph.D. / Senior Associate Scientist, Bioanalytical Sciences,
Biogen Idec, Cambridge, MA
11. HKA 11
1995-1996 Junzhi Li, Ph.D. / Instructor, Massachusetts General Hospital, Boston,
MA
1995-1997 Dan Hiregowdara, Ph.D. / Deceased
1995-1997 Byung H. Jhun, Ph.D. / Assistant Professor, Pusan National University,
South Korea
1995-1997 Setsuo Ota, Ph.D. / Assistant Professor, Chiba University, Japan
1995-2001 Dan Price, Ph.D. / BioSource-Tech, Houston, TX
1997-1999 Sheila Zrihan-Licht, Ph.D. / Scientist, Prochon Biotech, Ltd, Israel
1997-1999 Gina McShan, Ph.D. / Post-doc Fellow, Fox Chase Cancer Center,
Philadelphia, PA
1997 Martin Ellis, M.D. / Physician, Meir Hospital, Israel
1998 Julio J. Hajdenberg, M.D. / Physician, MD Anderson Cancer Center,
Orlando, FL
1998-1999 Yoshitaka Taniguchi, Ph.D. / Assistant Professor, Toray Research Center,
Japan
1998-1999 Hiroshi Yamashita, Ph.D. / Assistant Professor, Hiroshima University,
Japan
1998-2002 Cecile Bougeret, Ph.D. / Research Associate, Pasteur Institution, France
1999 Tihomir Miralem, Ph.D. / Scientist, University of Rochester, NY
1999 Xia Bu, Ph.D. / Post-doc Fellow, Harvard Medical School
1999-2000 Jakob Golab, Ph.D. / Research Associate, University of Warsaw, Poland
1999-2000 Katarzyna Koziak, Ph.D. / Research Associate, University of Warsaw,
Poland
1999-2001 Hitesh Jindal, Ph.D. / Assistant Professor, Alpert Medical School of
Brown University, RI
1999-2011 Huchun Li, Ph.D.
2000-2001 Joo-Won Suh, Ph.D.
2000-2001 Soyoun Kim, Ph.D. / Post-doc Fellow, University of Southern California,
CA
2000-2002 Hideki Kawai, M.D. / Physician, Fujita Health University, Japan
2000-2005 Byeong-Chel Lee, Ph.D. / Assistant Professor, University of Pittsburgh,
School of Medicine, PA
2000-2006 Iha Park, Ph.D. / Research Scientist, Korea
2000-2008 Radoslaw Zagozdzon, M.D., Ph.D. / Leader of Bioinformatics,
Department of Immunology, Medical University of Warsaw, Poland
2001-2002 Sun-Ok Kim, Ph.D. / Scientist, South Korea
2001-2005 Tae-Hee Lee, Ph.D. / Scientist, South Korea
2002-2004 Rafal Kaminski, M.D., Ph.D. / Physician-scientist, Poland
2004-2008 Elvis Tuburu, Ph.D. / Assistant Professor, Northeastern University,
Boston, MA
2005 Massimilliano Cerletti, Ph.D. / Post-doc Felow
2005-2007 Masayuki Sekine, M.D., Ph.D. / Physician-scientist, Japan
2006-2008 Cimona Hinton, M.D., Ph.D. / Assistant Professor, Clark Atlanta
University, GA
2007-2008 Jayone Ki, M.D. / Physician
2008-2010 Pedro L. Rodriguez, Ph.D. / Scientist, Roche Inc., Branchburg, NJ
12. HKA 12
2009-2010 Farheen Saddiqui
2010 Jinhua Quan, Ph.D. / Post-doc Fellow, Dana-Farber Cancer Institute
2010 Christopher Sy, B.S.
2010-2012 Lili Wang, B.S. / Master of Science in Biomedical Sciences Candidate,
Rutgers Graduate School of Biomedical Sciences, NJ
Research Students
7/1996-8/1999 Geertrui Spaepen
Lior Avraham
5/1997-6/2000 Sarah Rosner
6/1997-9/1998 Anupam Raychaudhuri
Edward Rhee
5/1999-8/1999 Jamal Misleh
6/2000-7/2000 Angell Shieh
5/2002-7/2002 Istok Miralem
6/2003-8/2003 Shy Steinberger
6/2004-8/2004 Akivah Steinberger
6/2005-8/2005 Noam Kimelman
6/2006-8/2006 Shiri Avraham
Rachel Weiss
5/2007-8/2007 Gabby Katz
5/2008-8/2008 Gabby Katz
5/2009-8/2009 Or-El Avraham
Gabby Bressler
5/2009-8/2010 Shiri Avraham
Benjamin Chen
Yehuda Stuchins
Lili Wang
5/2011-8/2011 Yehuda Stuchins
7/2013 Evan Cohen
REPORT OF REGIONAL, NATIONAL, AND INTERNATIONAL TEACHING
AND PRESENTATIONS
No presentations listed below were sponsored by outside entities.
National
1992 Interaction of Human Bone Marrow Fibroblasts with Megakaryocytes:
Role of the c-kit Ligand
Cleveland, OH (American Society of Hematology)
1992 Megakaryocytopoiesis and Platelet Production / Workshop
Bethesda, MD (National Institutes of Health)
1993 Identification and Characterization of a Novel Tyrosine Kinase from
Megakaryocytes
Cleveland, OH (American Society of Hematology)
1994 Modulation of Megakaryocytopoiesis by Human c-mpl Ligand
Cleveland, OH (American Society of Hematology)
1994 Structural and Functional Studies of the Intracellular Tyrosine Kinase
13. HKA 13
MATK Gene and its Translated Product
Cleveland, OH (American Society of Hematology)
1994 Tyrosine Kinases in Megakaryocytopoiesis
Keystone, CO (Keystone Symposia)
1995 Identification and Characterization of a Novel Related Adhesion Focal
Tyrosine Kinase (RAFTK) From Megakaryocytes and Brain
Cleveland, OH (American Society of Hematology)
1995 Characterization of Interaction of the Megakaryocyte-Associated Tyrosine
Kinase, MATK, with the c-kit Receptor
Cleveland, OH (American Society of Hematology)
1996 An Integrin (GpIIb/IIIa) Independent Phosphorylation of a Novel Related
Adhesion Focal Tyrosine Kinase (RAFTK) in Platelets
Cleveland, OH (American Society of Hematology)
1999 Functional Characterization of CHK as a Novel Negative Growth
Regulator of Human Breast Cancer
Philadelphia, PA (American Association for Cancer Research)
2000 Overexpression of the CSK Homologous (CHK) Inhibits Human Breast
Tumor Cell Growth
Philadelphia, PA (American Association for Cancer Research)
2000 VEGF Stimulation of Signaling in T-47D Breast Cancer Cells
Philadelphia, PA (American Association for Cancer Research)
2000 RAFTK/Pyk2 Tyrosine Kinase Mediates the Association of p190
RhoGAP with RasGAP in Breast Cancer Cells
Philadelphia, PA (American Association for Cancer Research)
2001 Functional analysis of Csk and CHK kinases in Breast Cancer Cells
New Orleans, LA (American Association for Cancer Research)
2001 Extracellular matrix enhances heregulin-dependent BRCA1
phosphorylation and suppresses BRCA1 expression through its C-
terminus in breast cancer cells
New Orleans, LA (American Association for Cancer Research)
2001 A novel BTB/POZ domain and kelch motif protein, Mayven, induces c-
jun/AP-1 activity and promotes cell cycle progression in human breast
cancer cells
New Orleans, LA (American Association for Cancer Research)
2001 A novel tricomplex of BRCA1, Nmi and c-Myc inhibits c-Myc induced
hTERT promoter activity in breast cancer
New Orleans, LA (American Association for Cancer Research)
2002 Breast Cancer Biology
Orlando, FL (Era of Hope, U.S. Department of Defense)
2004 Graduate Biology Lecture
New York, NY (Columbia University)
2005 Cardiology and Vascular Biology Lecture
San Diego, CA (San Diego State University)
2006 Barriers of the CNS
Gordon Research Conference (Tilton, NH)
2007 Angiogenic and Cell Survival Functions of VEGF and VEGFR-1 in
14. HKA 14
Breast Cancer Cells: Application to Anti-Angiogenesis Therapy
Baltimore, MD (National Institute on Aging, Gerontology Research
Center)
2007 Angiogenic and Cell Survival Functions of VEGF and VEGFR-1 in
Breast Cancer Cells
Indianapolis, IN (Indiana University-Purdue University Indianapolis)
2007 Angiogenic and Cell Survival Functions of VEGF and VEGFR-1 in
Breast Cancer Cells
Bethesda, MD (National Cancer Institute, Division of Cancer Biology)
2008 BRCA1 Regulates activation of beta-catenin/FOXO pathway During
Oxidative stress responses
East Lansing, MI (Michigan State University, Carcinogenesis Laboratory)
2008 Hematology Seminar
San Francisco, CA (American Society of Hematology)
2009 The Endocannabinoid System and HIV
Bethesda, MD (National Institute on Drug Abuse, National Institutes of
Health)
2010 The Interplay of Risk Factors, BRCA1 and Environment in Breast Cancer
Bethesda, MD (National Center on Minority Health and Health
Disparities, National Institutes of Health)
2010 The Interplay of Risk Factors, BRCA1 and Environment in Breast Cancer
New York, NY (Department of Environmental Medicine, NYU Langone
Medical Center)
2010 Role of BRCA1 in Oxidative Stress Mediated Responses
West Hollywood, CA (Cedars-Sinai Medical Center)
2012 Circulating Breast Tumor Cells Breaching the Blood-Brain Barrier and
Forming Tumor Colonies in Brain
Newark, NJ (Child Health Institute of New Jersey, Rutgers New Jersey
Medical School)
2012 Circulating breast tumor cells beaching the blood-brain barrier and
forming tumor colonies in brain
Summit, NJ (Celgene Corportation)
2012 Circulating breast tumor cells beaching the blood-brain barrier and
forming tumor colonies in brain
Augusta, GA (Georgia Health Sciences University Cancer Center)
2013 Role of Angiopoietin-2 in Breaching of the Blood-Brain Barrier by
Circulating Breast Tumor Cells
Stevenson, Washington (19th
Annual Blood-Brain Barrier Consortium
Meeting)
2013 Ang-2 As a Molecular Determinant in Triple Negative Breast Cancer Cell
Colonization in Brain
Norfolk, VA (College of Health Sciences, Old Dominion University)
2013 Breast Cancer and Breast Cancer Metastasis to Brain: Signaling Gone
Awry
Mt Pleasant, MI (Central Michigan University)
15. HKA 15
2013 Blood-Brain Barrier Impairment and Colonization of Triple Negative
Breast Cancer Cells in Brain
Mt Pleasant, MI (Central Michigan University)
International
2002 Oncology Lecture
Crete, Greece (7th
World Congress on Advances in Oncology and 5th
International Symposium on Molecular Medicine)
2006 Vascular and Cancer Biology Lecture
Jerusalem, Israel (Hadassah Medical School)
2011 Mechanisms for cannabinoid-mediated protective effects on HIV-1
Gp120 induced insult on brain endothelium
St. Charles, IL (International Cannabinoid Research Society)
REPORT OF TECHNOLOGICAL AND OTHER SCIENTIFIC INNOVATIONS
Differentiated megakaryocyte line
producing novel megakaryocyte
differentiation factor
US Patent: 5,686,576, filed 6/6/1994 / patft.uspto.gov
Differentiated megakaryocytes produced by
introducing an activated oncogene into blast-
megakaryocytes is disclosed. Also disclosed are novel
megakaryocyte differentiation factors and platelets
obtained from the differentiated megakaryocytes.
Neural cell protein marker RR/B and DNA
encoding same
US Patent: 5,863,744, filed 10/3/1994 /
patft.uspto.gov
The invention contemplates the novel neural cell
protein marker RR/B, cDNA encoding RR/B, nucleic
acid probes for detection of mRNA encoding RR/B,
synthetic polypeptides whose sequences correspond to
a portion of RR/B and have a molecular weight equal
to less than that of RR/B, and methods for detection of
RR/B.
Neural cell protein marker RR/B and DNA
encoding the same
US Patent: 6,066,451, filed 10/3/1994 /
patft.uspto.gov
The invention contemplates the novel neural cell
protein marker RR/B, cDNA encoding RR/B, nucleic
acid probes for detection of mRNA encoding RR/B,
synthetic polypeptides whose sequences correspond to
a portion of RR/B and have a molecular weight equal
to less than that of RR/B antibodies specific for RR/B,
and methods for detection of RR/B.
Methods and kits using macrophage
stimulating protein
US Patent: 5,696,086, filed 11/3/1994 /
patft.uspto.gov
The invention provides methods for stimulating
megakaryocyte maturation and thrombocyte
production using macrophage stimulating protein
16. HKA 16
("MSP"). In the methods, an effective amount of MSP
can be administered in vivo, or alternatively, be used
to stimulate maturation of megakaryocytes and
produce thrombocytes in vitro. Methods for treating
thrombocytopenia in a mammal with MSP are also
provided. Kits and articles of manufacture which
include MSP are further provided.
Methods of detection and treatment of
breast cancer
US Patent: 5,981,201, filed 6/16/1997 /
patft.uspto.gov
Novel methods of detecting and treating breast cancer
are described.
Agonist murine monoclonal antibody as a
stimulant for megakaryocytopoiesis
US Patent: 5,980,893, filed 7/17/1997 /
patft.uspto.gov
A class of murine monoclonal antibodies that is
capable of stimulating megakaryocytopoiesis in vitro
has been raised against human megakaryocytic cells.
The monoclonal antibody BAH-1 specifically
recognizes and demonstrates agonist activity against
the c-Mpl receptor on the megakaryocytic cell surface.
In therapeutic applications, the BAH-1 and M4
monoclonal antibodies identified to date and similar
antibodies (or active portions and chimeric
combinations thereof) can stimulate proliferation of
primary bone marrow megakaryocytes. Thus, the
antibodies of the invention can be used to prepare a
composition for treating, e.g., thrombocytopenia. A
typical composition comprises a therapeutically
effective amount of the BAH-1 monoclonal antibody
in association with a pharmaceutically acceptable
carrier vehicle.
Methods of detection and treatment of
breast cancer
US Patent: 6,638,769, filed 5/20/1999 /
patft.uspto.gov
Novel methods of detecting and treating breast cancer
are described.
REPORT OF SCHOLARSHIP
Peer-Reviewed Publications in Print
Research Investigations
1. Avraham, H., D.T. Spira, Y. Gorsky, and D. Sulitzeanu, A solid-phase antibody binding-
inhibition test, for the assay of Plasmodium berghei antigen and antibodies, using
radioiodinated protein A. J Immunol Methods, 1980. 32(2): p. 151-155.
2. Avraham, H., J. Golenser, D.T. Spira, and D. Sulitzeanu, Plasmodium falciparum: assay
of antigens and antibodies by means of a solid phase radioimmunoassay with
radioiodinated staphylococcal protein A. Trans R Soc Trop Med Hyg, 1981. 75(3): p.
421-425.
17. HKA 17
3. Ronai, Z., H. Avraham, and D. Sulitzeanu, Autoantibodies to red blood cells in rats
infected with Plasmodium berghei. J Parasitol, 1981. 67(3): p. 351-354.
4. Avraham, H., J. Golenser, Y. Gazitt, D.T. Spira, and D. Sulitzeanu, A highly sensitive
solid-phase radioimmunoassay for the assay of Plasmodium falciparum antigens and
antibodies. J Immunol Methods, 1982. 53(1): p. 61-68.
5. Avraham, H., D.T. Spira, and D. Sulitzeanu, Inhibition of antibody-binding as a
radioimmunoassay for Plasmodium berghei infection in rats. J Parasitol, 1982. 68(2): p.
177-184.
6. Avraham, H., J. Golenser, D. Bunnag, P. Suntharasamai, S. Tharavanij, K.T. Harinasuta,
D.T. Sira, and D. Sulitzeanu, Preliminary field trial of a radioimmunoassay for the
diagnosis of malaria. Am J Trop Med Hyg, 1983. 32(1): p. 11-18.
7. El-On, J., U. Zehavi, H. Avraham, and C.L. Greenblatt, Leishmania tropica and
Leishmania donovani: solid phase radioimmunoassay using leishmanial excreted factor.
Exp Parasitol, 1983. 55(3): p. 270-279.
8. Golenser, J., J. Miller, H. Avraham, and D.T. Spira, The inhibitory effect of human
immune sera upon the in vitro development of Plasmodium falciparum. Trop Geogr Med,
1983. 35(1): p. 15-20.
9. Berrebi, A., Z. Eshhar, S. Linder, L. Guedj, and H. Avraham, RAB-1: a new monoclonal
antibody to leukemic hairy cells. Leuk Res, 1986. 10(9): p. 1071-1078.
10. Livneh, A., H. Avraham, D. Elias, J. Sack, I.R. Cohen, and Z. Eshhar, A human
monoclonal antibody to insulin. Diabetes, 1986. 35(1): p. 68-73.
11. Avraham, H., S. Avraham, and S.C. Bernstein, A rapid procedure for cell colony
hybridization using DNA probes. Anal Biochem, 1989. 179(2): p. 217-221.
12. Avraham, H. and R.A. Weinberg, Characterization and expression of the human
rhoH12 gene product. Mol Cell Biol, 1989. 9(5): p. 2058-2066.
13. Avraham, H., rho gene amplification and malignant transformation. Biochem Biophys
Res Commun, 1990. 168(1): p. 114-124.
14. Livneh, A., H. Avraham, T. Bistritzer, L. Weisglass, R. Theodor, and J. Sack,
Deleterious effect of anti-insulin antibodies on diabetes control. Isr J Med Sci, 1990.
26(1): p. 11-15.
15. Avraham, H., E. Vannier, S.Y. Chi, C.A. Dinarello, and J.E. Groopman, Cytokine gene
expression and synthesis by human megakaryocytic cells. Int J Cell Cloning, 1992. 10(2):
p. 70-79.
16. Avraham, H., E. Vannier, S. Cowley, S.X. Jiang, S. Chi, C.A. Dinarello, K.M. Zsebo,
and J.E. Groopman, Effects of the stem cell factor, c-kit ligand, on human megakaryocytic
cells. Blood, 1992. 79(2): p. 365-371.
17. Avraham, S., H. Avraham, K.F. Austen, and R.L. Stevens, Negative and positive cis-
acting elements in the promoter of the mouse gene that encodes the serine/glycine-rich
peptide core of secretory granule proteoglycans. J Biol Chem, 1992. 267(1): p. 610-617.
18. Cowley, S.A., J.E. Groopman, and H. Avraham, Effects of transforming growth factor
beta on megakaryocytic cell fusion and endomitosis. Int J Cell Cloning, 1992. 10(4): p.
223-231.
19. Avraham, H., S. Cowley, S.Y. Chi, S. Jiang, and J.E. Groopman, Characterization of
adhesive interactions between human endothelial cells and megakaryocytes. J Clin
Invest, 1993. 91(6): p. 2378-2384.
18. HKA 18
20. Hauser, C., S. Avraham, and H. Avraham, Association of rho proteins with the
mitochondria organelle. Int J Oncol, 1993. 3(6): p. 1103-1110.
21. Avraham, H., N. Banu, D.T. Scadden, J. Abraham, and J.E. Groopman, Modulation of
megakaryocytopoiesis by human basic fibroblast growth factor. Blood, 1994. 83(8): p.
2126-2132.
22. Avraham, H., G. Erdos, and Y. Gazitt, Differential expression and subcellular-
localization of protein-kinase-C, alpha, gamma, delta, xi and zeta isoforms in agf T-cells
- modification during pma-induced differentiation. Int J Oncol, 1994. 5(2): p. 237-241.
23. Bennett, B.D., S. Cowley, S. Jiang, R. London, B. Deng, J. Grabarek, J.E. Groopman,
D.V. Goeddel, and H. Avraham, Identification and characterization of a novel tyrosine
kinase from megakaryocytes. J Biol Chem, 1994. 269(2): p. 1068-1074.
24. Grabarek, J., J.E. Groopman, Y.R. Lyles, S. Jiang, L. Bennett, K. Zsebo, and H.
Avraham, Human kit ligand (stem cell factor) modulates platelet activation in vitro. J
Biol Chem, 1994. 269(34): p. 21718-21724.
25. Jiang, S., J.D. Levine, Y. Fu, B. Deng, R. London, J.E. Groopman, and H. Avraham,
Cytokine production by primary bone marrow megakaryocytes. Blood, 1994. 84(12): p.
4151-4156.
26. Avraham, H., M.H. Ellis, B.H. Jhun, S. Raja, D. Chalasani, and S. Avraham, Tyrosine
kinases in megakaryocytopoiesis. Stem Cells, 1995. 13(4): p. 380-392.
27. Avraham, S., S. Jiang, S. Ota, Y. Fu, B. Deng, L.L. Dowler, R.A. White, and H.
Avraham, Structural and functional studies of the intracellular tyrosine kinase MATK
gene and its translated product. J Biol Chem, 1995. 270(4): p. 1833-1842.
28. Avraham, S., R. London, Y. Fu, S. Ota, D. Hiregowdara, J. Li, S. Jiang, L.M. Pasztor,
R.A. White, J.E. Groopman, and H. Avraham, Identification and characterization of a
novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J
Biol Chem, 1995. 270(46): p. 27742-27751.
29. Banu, N., J.F. Wang, B. Deng, J.E. Groopman, and H. Avraham, Modulation of
megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand. Blood, 1995. 86(4): p. 1331-
1338.
30. Jhun, B.H., B. Rivnay, D. Price, and H. Avraham, The MATK tyrosine kinase interacts
in a specific and SH2-dependent manner with c-Kit. J Biol Chem, 1995. 270(16): p.
9661-9666.
31. Lee, J., A. Gray, J. Yuan, S.M. Luoh, H. Avraham, and W.I. Wood, Vascular
endothelial growth factor-related protein: a ligand and specific activator of the tyrosine
kinase receptor Flt4. Proc Natl Acad Sci U S A, 1996. 93(5): p. 1988-1992.
32. Li, J., H. Avraham, R.A. Rogers, S. Raja, and S. Avraham, Characterization of RAFTK,
a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation
in megakaryocytes. Blood, 1996. 88(2): p. 417-428.
33. Nimer, S., J. Zhang, H. Avraham, and Y. Miyazaki, Transcriptional regulation of
interleukin-3 expression in megakaryocytes. Blood, 1996. 88(1): p. 66-74.
34. Salgia, R., S. Avraham, E. Pisick, J.L. Li, S. Raja, E.A. Greenfield, M. Sattler, H.
Avraham, and J.D. Griffin, The related adhesion focal tyrosine kinase forms a complex
with paxillin in hematopoietic cells. J Biol Chem, 1996. 271(49): p. 31222-31226.
35. Astier, A., H. Avraham, S.N. Manie, J. Groopman, T. Canty, S. Avraham, and A.S.
Freedman, The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after
19. HKA 19
beta1-integrin stimulation in B cells and binds to p130cas. J Biol Chem, 1997. 272(1): p.
228-232.
36. Astier, A., S.N. Manie, H. Avraham, H. Hirai, S.F. Law, Y. Zhang, E.A. Golemis, Y.
Fu, B.J. Druker, N. Haghayeghi, A.S. Freedman, and S. Avraham, The related adhesion
focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein,
p105HEF1. J Biol Chem, 1997. 272(32): p. 19719-19724.
37. Avraham, S., R. London, G.A. Tulloch, M. Ellis, Y. Fu, S. Jiang, R.A. White, C. Painter,
A.A. Steinberger, and H. Avraham, Characterization and chromosomal localization of
PTPRO, a novel receptor protein tyrosine phosphatase, expressed in hematopoietic stem
cells. Gene, 1997. 204(1-2): p. 5-16.
38. Ganju, R.K., W.C. Hatch, H. Avraham, M.A. Ona, B. Druker, S. Avraham, and J.E.
Groopman, RAFTK, a novel member of the focal adhesion kinase family, is
phosphorylated and associates with signaling molecules upon activation of mature T
lymphocytes. J Exp Med, 1997. 185(6): p. 1055-1063.
39. Hiregowdara, D., H. Avraham, Y. Fu, R. London, and S. Avraham, Tyrosine
phosphorylation of the related adhesion focal tyrosine kinase in megakaryocytes upon
stem cell factor and phorbol myristate acetate stimulation and its association with
paxillin. J Biol Chem, 1997. 272(16): p. 10804-10810.
40. Manie, S.N., A.R. Beck, A. Astier, S.F. Law, T. Canty, H. Hirai, B.J. Druker, H.
Avraham, N. Haghayeghi, M. Sattler, R. Salgia, J.D. Griffin, E.A. Golemis, and A.S.
Freedman, Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein,
in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen
receptor on human B cells. J Biol Chem, 1997. 272(7): p. 4230-4236.
41. Price, D.J., B. Rivnay, Y. Fu, S. Jiang, S. Avraham, and H. Avraham, Direct association
of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the
activated c-KIT in megakaryocytes. J Biol Chem, 1997. 272(9): p. 5915-5920.
42. Raja, S., S. Avraham, and H. Avraham, Tyrosine phosphorylation of the novel protein-
tyrosine kinase RAFTK during an early phase of platelet activation by an integrin
glycoprotein IIb-IIIa-independent mechanism. J Biol Chem, 1997. 272(16): p. 10941-
10947.
43. Wang, J.F., R.K. Ganju, Z.Y. Liu, H. Avraham, S. Avraham, and J.E. Groopman, Signal
transduction in human hematopoietic cells by vascular endothelial growth factor related
protein, a novel ligand for the FLT4 receptor. Blood, 1997. 90(9): p. 3507-3515.
44. Zrihan-Licht, S., J. Lim, I. Keydar, M.X. Sliwkowski, J.E. Groopman, and H. Avraham,
Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in
breast cancer cells. J Biol Chem, 1997. 272(3): p. 1856-1863.
45. Deng, B., N. Banu, B. Malloy, P. Hass, J.F. Wang, L. Cavacini, D. Eaton, and H.
Avraham, An agonist murine monoclonal antibody to the human c-Mpl receptor
stimulates megakaryocytopoiesis. Blood, 1998. 92(6): p. 1981-1988.
46. Jiang, S., A.G. Tulloch, T.A. Kim, Y. Fu, R. Rogers, A. Gaskell, R.A. White, H.
Avraham, and S. Avraham, Characterization and chromosomal localization of PTP-NP-
2, a new isoform of protein tyrosine phosphatase-like receptor, expressed on synaptic
boutons. Gene, 1998. 215(2): p. 345-359.
47. Kim, T.A., J. Lim, S. Ota, S. Raja, R. Rogers, B. Rivnay, H. Avraham, and S. Avraham,
NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in
neuronal differentiation. J Cell Biol, 1998. 141(3): p. 553-566.
20. HKA 20
48. Sato, T., A. Fuse, H. Niimi, P.J. Fielder, and H. Avraham, Binding and regulation of
thrombopoietin to human megakaryocytes. Br J Haematol, 1998. 100(4): p. 704-711.
49. Soltoff, S.P., H. Avraham, S. Avraham, and L.C. Cantley, Activation of P2Y2 receptors
by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that
involves related adhesion focal tyrosine kinase and protein kinase C. J Biol Chem, 1998.
273(5): p. 2653-2660.
50. Zhang, Z., H. Avraham, and D.M. Cohen, Urea and NaCl differentially regulate FAK
and RAFTK/PYK2 in mIMCD3 renal medullary cells. Am J Physiol, 1998. 275(3 Pt 2): p.
447-451.
51. Zrihan-Licht, S., B. Deng, Y. Yarden, G. McShan, I. Keydar, and H. Avraham, Csk
homologous kinase, a novel signaling molecule, directly associates with the activated
ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J Biol Chem,
1998. 273(7): p. 4065-4072.
52. Altiok, S., D. Batt, N. Altiok, A. Papautsky, J. Downward, T.M. Roberts, and H.
Avraham, Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-
Kinase/AKT in breast cancer cells. J Biol Chem, 1999. 274(45): p. 32274-32278.
53. H. Avraham, and D.J. Price, Regulation of megakaryocytopoiesis and platelet
production by tyrosine kinases and tyrosine phosphatases. Methods, 1999. 17(3): p. 250-
264.
54. Banu, N., B. Deng, S.D. Lyman, and H. Avraham, Modulation of haematopoietic
progenitor development by FLT-3 ligand. Cytokine, 1999. 11(9): p. 679-688.
55. Gerwin, N., J.A. Gonzalo, C. Lloyd, A.J. Coyle, Y. Reiss, N. Banu, B. Wang, H. Xu, H.
Avraham, B. Engelhardt, T.A. Springer, and J.C. Gutierrez-Ramos, Prolonged
eosinophil accumulation in allergic lung interstitium of ICAM-2 deficient mice results in
extended hyperresponsiveness. Immunity, 1999. 10(1): p. 9-19.
56. Pandey, P., S. Avraham, S. Kumar, A. Nakazawa, A. Place, L. Ghanem, A. Rana, V.
Kumar, P.K. Majumder, H. Avraham, R.J. Davis, and S. Kharbanda, Activation of p38
mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-
dependent mechanism. J Biol Chem, 1999. 274(15): p. 10140-10144.
57. Price, D.J., B. Rivnay, and H. Avraham, CHK down-regulates SCF/KL-activated Lyn
kinase activity in Mo7e megakaryocytic cells. Biochem Biophys Res Commun, 1999.
259(3): p. 611-616.
58. Soltysik-Espanola, M., R.A. Rogers, S. Jiang, T.A. Kim, R. Gaedigk, R.A. White, H.
Avraham, and S. Avraham, Characterization of Mayven, a novel actin-binding protein
predominantly expressed in brain. Mol Biol Cell, 1999. 10(7): p. 2361-2375.
59. Taniguchi, Y., R. London, K. Schinkmann, S. Jiang, and H. Avraham, The receptor
protein tyrosine phosphatase, PTP-RO, is upregulated during megakaryocyte
differentiation and Is associated with the c-Kit receptor. Blood, 1999. 94(2): p. 539-549.
60. van Os, R., H. Avraham, N. Banu, P.M. Mauch, J. Whater, Y. Yang, and B. Du,
Recombinant adeno-associated virus-based vectors provide short-term rather than long-
term transduction of primitive hematopoietic stem cells. Stem Cells, 1999. 17(2): p. 117-
120.
61. Yamashita, H., S. Avraham, S. Jiang, I. Dikic, and H. Avraham, The Csk homologous
kinase associates with TrkA receptors and is involved in neurite outgrowth of PC12 cells.
J Biol Chem, 1999. 274(21): p. 15059-15065.
21. HKA 21
62. Yamashita, H., S. Avraham, S. Jiang, R. London, P.P. Van Veldhoven, S. Subramani,
R.A. Rogers, and H. Avraham, Characterization of human and murine PMP20
peroxisomal proteins that exhibit antioxidant activity in vitro. J Biol Chem, 1999.
274(42): p. 29897-29904.
63. Avraham, H., S. Avraham, and Y. Taniguchi, Receptor protein tyrosine phosphatases in
hematopoietic cells. J Hematother Stem Cell Res, 2000. 9(4): p. 425-432.
64. Avraham, H., S.Y. Park, K. Schinkmann, and S. Avraham, RAFTK/Pyk2-mediated
cellular signalling. Cell Signal, 2000. 12(3): p. 123-133.
65. Park, S.Y., H. Avraham, and S. Avraham, Characterization of the tyrosine kinases
RAFTK/Pyk2 and FAK in nerve growth factor-induced neuronal differentiation. J Biol
Chem, 2000. 275(26): p. 19768-19777.
66. Radisavljevic, Z., H. Avraham, and S. Avraham, Vascular endothelial growth factor up-
regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide
pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem,
2000. 275(27): p. 20770-20774.
67. Zrihan-Licht, S., Y. Fu, J. Settleman, K. Schinkmann, L. Shaw, I. Keydar, S. Avraham,
and H. Avraham, RAFTK/Pyk2 tyrosine kinase mediates the association of p190
RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene, 2000.
19(10): p. 1318-1328.
68. Bougeret, C., S. Jiang, I. Keydar, and H. Avraham, Functional analysis of Csk and CHK
kinases in breast cancer cells. J Biol Chem, 2001. 276(36): p. 33711-33720.
69. Koziak, K., E. Kaczmarek, S.Y. Park, Y. Fu, S. Avraham, and H. Avraham,
RAFTK/Pyk2 involvement in platelet activation is mediated by phosphoinositide 3-kinase.
Br J Haematol, 2001. 114(1): p. 134-140.
70. Miralem, T., R. Steinberg, D. Price, and H. Avraham, VEGF(165) requires extracellular
matrix components to induce mitogenic effects and migratory response in breast cancer
cells. Oncogene, 2001. 20(39): p. 5511-5524.
71. Price, D.J., T. Miralem, S. Jiang, R. Steinberg, and H. Avraham, Role of vascular
endothelial growth factor in the stimulation of cellular invasion and signaling of breast
cancer cells. Cell Growth Differ, 2001. 12(3): p. 129-135.
72. Banu, N., S. Avraham, and H.K. Avraham, P-selectin, and not E-selectin, negatively
regulates murine megakaryocytopoiesis. J Immunol, 2002. 169(8): p. 4579-4585.
73. Kawai, H., H. Li, P. Chun, S. Avraham, and H.K. Avraham, Direct interaction between
BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF)
transcription and secretion in breast cancer cells. Oncogene, 2002. 21(50): p. 7730-
7739.
74. Kim, S., R. Zagozdzon, A. Meisler, J.D. Baleja, Y. Fu, S. Avraham, and H. Avraham,
Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK
negative growth regulatory function in breast cancer. J Biol Chem, 2002. 277(39): p.
36465-36470.
75. Lee, T.-H., H. Avraham, S.-H. Lee, and S. Avraham, Vascular endothelial growth factor
modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in
human brain microvascular endothelial cells. J Biol Chem, 2002. 277(12): p. 10445-
10451.
22. HKA 22
76. Li, H., T.-H. Lee, and H. Avraham, A novel tricomplex of BRCA1, Nmi, and c-Myc
inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter
activity in breast cancer. J Biol Chem, 2002. 277(23): p. 20965-20973.
77. Li, X., X. Bu, B. Lu, H. Avraham, R.A. Flavell, and B. Lim, The hematopoiesis-specific
GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho
GTPases by an inhibitory function. Mol Cell Biol, 2002. 22(4): p. 1158-1171.
78. McShan, G.D., R. Zagozdzon, S.-Y. Park, S. Zrihan-Licht, Y. Fu, S. Avraham, and H.
Avraham, Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells
and negatively regulates its activation and breast cancer cell migration. Int J Oncol,
2002. 21(1): p. 197-205.
79. Melendez, J., S. Welch, E. Schaefer, C.S. Moravec, S. Avraham, H. Avraham, and
M.A. Sussman, Activation of pyk2/related focal adhesion tyrosine kinase and focal
adhesion kinase in cardiac remodeling. J Biol Chem, 2002. 277(47): p. 45203-45210.
80. Nakamura, T., H. Yamashita, Y. Nagano, T. Takahashi, S. Avraham, H. Avraham, M.
Matsumoto, and S. Nakamura, Activation of Pyk2/RAFTK induces tyrosine
phosphorylation of alpha-synuclein via Src-family kinases. FEBS Lett, 2002. 521(1-3): p.
190-194.
81. Price, D.J., S. Avraham, J. Feuerstein, Y. Fu, and H.K. Avraham, The invasive
phenotype in HMT-3522 cells requires increased EGF receptor signaling through both
PI 3-kinase and ERK 1,2 pathways. Cell Commun Adhes, 2002. 9(2): p. 87-8102.
82. Zagozdzon, R., C. Bougeret, Y. Fu, and H.K. Avraham, Overexpression of the Csk
homologous kinase facilitates phosphorylation of Akt/PKB in MCF-7 cells. Int J Oncol,
2002. 21(6): p. 1347-1352.
83. Avraham, H.K., T.-H. Lee, Y. Koh, T.-A. Kim, S. Jiang, M. Sussman, A.M. Samarel,
and S. Avraham, Vascular endothelial growth factor regulates focal adhesion assembly
in human brain microvascular endothelial cells through activation of the focal adhesion
kinase and related adhesion focal tyrosine kinase. J Biol Chem, 2003. 278(38): p. 36661-
36668.
84. Kawai, H., H. Li, S. Avraham, S. Jiang, and H.K. Avraham, Overexpression of histone
deacetylase HDAC1 modulates breast cancer progression by negative regulation of
estrogen receptor alpha. Int J Cancer, 2003. 107(3): p. 353-358.
85. Kim, T.-A., H.K. Avraham, Y.-H. Koh, S. Jiang, I.-W. Park, and S. Avraham, HIV-1
Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol,
2003. 170(5): p. 2629-2637.
86. Miralem, T. and H.K. Avraham, Extracellular matrix enhances heregulin-dependent
BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. Mol
Cell Biol, 2003. 23(2): p. 579-593.
87. Price, D., I. Park, and H. Avraham, Methods for the study of protein-protein interactions
in cancer cell biology. Methods Mol Biol, 2003. 218: p. 255-267.
88. Takahashi, T., H. Yamashita, Y. Nagano, T. Nakamura, H. Ohmori, H. Avraham, S.
Avraham, M. Yasuda, and M. Matsumoto, Identification and characterization of a novel
Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-
synuclein phosphorylation. J Biol Chem, 2003. 278(43): p. 42225-42233.
89. Avraham, H.K., S. Jiang, T.-H. Lee, O. Prakash, and S. Avraham, HIV-1 Tat-mediated
effects on focal adhesion assembly and permeability in brain microvascular endothelial
cells. J Immunol, 2004. 173(10): p. 6228-6233.
23. HKA 23
90. Kim, S.-O., S. Avraham, S. Jiang, R. Zagozdzon, Y. Fu, and H.K. Avraham, Differential
expression of Csk homologous kinase (CHK) in normal brain and brain tumors. Cancer,
2004. 101(5): p. 1018-1027.
91. Lee, B.-C., K. Cha, S. Avraham, and H.K. Avraham, Microarray analysis of
differentially expressed genes associated with human ovarian cancer. Int J Oncol, 2004.
24(4): p. 847-851.
92. Lee, B.-C., T.-H. Lee, S. Avraham, and H.K. Avraham, Involvement of the chemokine
receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell
migration through human brain microvascular endothelial cells. Mol Cancer Res, 2004.
2(6): p. 327-338.
93. Liang, X.-Q., H.K. Avraham, S. Jiang, and S. Avraham, Genetic alterations of the
NRP/B gene are associated with human brain tumors. Oncogene, 2004. 23(35): p. 5890-
5900.
94. Melendez, J., C. Turner, H. Avraham, S.F. Steinberg, E. Schaefer, and M.A. Sussman,
Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by
paxillin. J Biol Chem, 2004. 279(51): p. 53516-53523.
95. Park, S.-Y., H.K. Avraham, and S. Avraham, RAFTK/Pyk2 activation is mediated by
trans-acting autophosphorylation in a Src-independent manner. J Biol Chem, 2004.
279(32): p. 33315-33322.
96. Price, D.J., S. Avraham, S. Jiang, Y. Fu, and H.K. Avraham, Role of the aging
vasculature and Erb B-2 signaling in epidermal growth factor-dependent intravasion of
breast carcinoma cells. Cancer, 2004. 101(1): p. 198-205.
97. Zrihan-Licht, S., S. Avraham, S. Jiang, Y. Fu, and H.K. Avraham, Coupling of
RAFTK/Pyk2 kinase with c-Abl and their role in the migration of breast cancer cells. Int
J Oncol, 2004. 24(1): p. 153-159.
98. Bu, X., H.K. Avraham, X. Li, B. Lim, S. Jiang, Y. Fu, R.G. Pestell, and S. Avraham,
Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells.
Oncogene, 2005. 24(14): p. 2398-2409.
99. Jiang, S., H.K. Avraham, S.-Y. Park, T.-A. Kim, X. Bu, S. Seng, and S. Avraham,
Process elongation of oligodendrocytes is promoted by the Kelch-related actin-binding
protein Mayven. J Neurochem, 2005. 92(5): p. 1191-1203.
100. Kim, T.-A., S. Jiang, S. Seng, K. Cha, H.K. Avraham, and S. Avraham, The BTB
domain of the nuclear matrix protein NRP/B is required for neurite outgrowth. J Cell Sci,
2005. 118(Pt 23): p. 5537-5548.
101. Lee, B.-C., T.-H. Lee, R. Zagozdzon, S. Avraham, A. Usheva, and H.K. Avraham,
Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine
receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated
breast cancer cell migration. Cancer Res, 2005. 65(7): p. 2840-2845.
102. Zhang, J., J. Zhu, X. Bu, M. Cushion, T.B. Kinane, H. Avraham, and H. Koziel, Cdc42
and RhoB activation are required for mannose receptor-mediated phagocytosis by human
alveolar macrophages. Mol Biol Cell, 2005. 16(2): p. 824-834.
103. Fu, Y., R. Zagozdzon, R. Avraham, and H.K. Avraham, CHK negatively regulates Lyn
kinase and suppresses pancreatic cancer cell invasion. Int J Oncol, 2006. 29(6): p. 1453-
1458.
24. HKA 24
104. Jiang, S., H.K. Avraham, T.-A. Kim, R.A. Rogers, and S. Avraham, Receptor-type PTP-
NP inhibition of Dynamin-1 GTPase activity is associated with neuronal depolarization.
Cell Signal, 2006. 18(9): p. 1439-1446.
105. Kaminski, R., R. Zagozdzon, Y. Fu, P. Mroz, W. Fu, S. Seng, S. Avraham, and H.K.
Avraham, Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm
using Csk homologous kinase transgenic mice. Cancer Res, 2006. 66(11): p. 5757-5762.
106. Klein, B.Y., S.D. Tachado, H. Koziel, and H.K. Avraham, Protein changes typical for
therapy-resistant cancer cells appear in MCF7 breast cancer cultures as early as one
doubling time after chemical treatment. Int J Canc Res, 2006. 2(2): p. 161-175.
107. Lee, B.-C., S. Avraham, A. Imamoto, and H.K. Avraham, Identification of the
nonreceptor tyrosine kinase MATK/CHK as an essential regulator of immune cells using
Matk/CHK-deficient mice. Blood, 2006. 108(3): p. 904-907.
108. Lee, T.-H., S. Seng, H. Li, S.J. Kennel, H.K. Avraham, and S. Avraham, Integrin
regulation by vascular endothelial growth factor in human brain microvascular
endothelial cells: role of alpha6beta1 integrin in angiogenesis. J Biol Chem, 2006.
281(52): p. 40450-40460.
109. Park, I. and H.K. Avraham, Cell cycle-dependent DNA damage signaling induced by
ICRF-193 involves ATM, ATR, CHK2, and BRCA1. Exp Cell Res, 2006. 312(11): p.
1996-2008.
110. Seng, S., H.K. Avraham, S. Jiang, S. Venkatesh, and S. Avraham, KLHL1/MRP2
mediates neurite outgrowth in a glycogen synthase kinase 3beta-dependent manner. Mol
Cell Biol, 2006. 26(22): p. 8371-8384.
111. Tiburu, E.K., E.S. Karp, G. Birrane, J.O. Struppe, S. Chu, G.A. Lorigan, S. Avraham, and
H.K. Avraham, 31P and 2H relaxation studies of helix VII and the cytoplasmic helix of
the human cannabinoid receptors utilizing solid-state NMR techniques. Biochemistry,
2006. 45(23): p. 7356-7365.
112. Zagozdzon, R., R. Kaminski, Y. Fu, W. Fu, C. Bougeret, and H.K. Avraham, Csk
homologous kinase (CHK), unlike Csk, enhances MAPK activation via Ras-mediated
signaling in a Src-independent manner. Cell Signal, 2006. 18(6): p. 871-881.
113. Avraham, S., S. Seng, S. Jiang, and H.K. Avraham, ENC1 (ectodermal-neural cortex
(with BTB-like domain)). Atlas Genet Cytogenet Oncol Haematol, 2007.
114. Jiang, S., Y. Fu, J. Williams, J. Wood, L. Pandarinathan, S. Avraham, A. Makriyannis, S.
Avraham, and H.K. Avraham, Expression and function of cannabinoid receptors CB1
and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS
One, 2007. 2(7).
115. Jiang, S., S. Seng, H.K. Avraham, Y. Fu, and S. Avraham, Process elongation of
oligodendrocytes is promoted by the Kelch-related protein MRP2/KLHL1. J Biol Chem,
2007. 282(16): p. 12319-12329.
116. Lee, T.-H., S. Seng, M. Sekine, C. Hinton, Y. Fu, H.K. Avraham, and S. Avraham,
Vascular endothelial growth factor mediates intracrine survival in human breast
carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med, 2007. 4(6).
117. Seng, S., H.K. Avraham, S. Jiang, S. Yang, M. Sekine, N. Kimelman, H. Li, and S.
Avraham, The nuclear matrix protein, NRP/B, enhances Nrf2-mediated oxidative stress
responses in breast cancer cells. Cancer Res, 2007. 67(18): p. 8596-8604.
25. HKA 25
118. Tiburu, E.K., C.E. Bass, J.O. Struppe, G.A. Lorigan, S. Avraham, and H.K. Avraham,
Structural divergence among cannabinoids influences membrane dynamics: a 2H solid-
state NMR analysis. Biochim Biophys Acta, 2007. 1768(9): p. 2049-2059.
119. Hinton, C.V., S. Avraham, and H.K. Avraham, Contributions of integrin-linked kinase
to breast cancer metastasis and tumourigenesis. J Cell Mol Med, 2008. 12(5A): p. 1517-
1526.
120. Lu, T.-S., H.K. Avraham, S. Seng, S.D. Tachado, H. Koziel, A. Makriyannis, and S.
Avraham, Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular
endothelial cells. J Immunol, 2008. 181(9): p. 6406-6416.
121. Zagozdzon, R., Y. Fu, and H.K. Avraham, Csk homologous kinase inhibits CXCL12-
CXCR4 signaling in neuroblastoma. Int J Oncol, 2008. 32(3): p. 619-623.
122. Alberich Jorda M, J.S., Zagozdzon R, Parmar K, Mauch P, Fu Y, Makriyannis A, Zvonok
AM, Tenen DG, Avraham S, Groopman JE, Avraham HK, The peripheral cannabinoid
receptor regulates human and mouse hematopoiesis, bone marrow recovery, and
hematopoietic stem and progenitor cell mobilization, in Haematologica. 2009. p. 208.
123. Li, H., M. Sekine, S. Seng, S. Avraham, and H.K. Avraham, BRCA1 interacts with
Smad3 and regulates Smad3-mediated TGF-beta signaling during oxidative stress
responses. PLoS One, 2009. 4(9).
124. Seng, S., H.K. Avraham, G. Birrane, S. Jiang, H. Li, G. Katz, C.E. Bass, R. Zagozdzon,
and S. Avraham, NRP/B mutations impair Nrf2-dependent NQO1 induction in human
primary brain tumors. Oncogene, 2009. 28(3): p. 378-389.
125. Tiburu, E.K., A.L. Bowman, J.O. Struppe, D.R. Janero, H.K. Avraham, and A.
Makriyannis, Solid-state NMR and molecular dynamics characterization of cannabinoid
receptor-1 (CB1) helix 7 conformational plasticity in model membranes. Biochim
Biophys Acta, 2009. 1788(5): p. 1159-1167.
126. Arshad, F., L. Wang, C. Sy, S. Avraham, and H.K. Avraham, Blood-brain barrier
integrity and breast cancer metastasis to the brain. Patholog Res Int, 2010. 2011: p.
920509-920509.
127. Hinton, C.V., S. Avraham, and H.K. Avraham, Role of the CXCR4/CXCL12 signaling
axis in breast cancer metastasis to the brain. Clin Exp Metastasis, 2010. 27(2): p. 97-
9105.
128. Jiang, S., B.C. Lee, Y. Fu, S. Avraham, B. Lim, and H.K. Avraham, Reconstitution of
mammary epithelial morphogenesis by murine embryonic stem cells undergoing
hematopoietic stem cell differentiation. PLoS One, 2010. 5(3): p. e9707.
129. Li, H., M. Sekine, N. Tung, and H.K. Avraham, Wild-type BRCA1, but not mutated
BRCA1, regulates the expression of the nuclear form of beta-catenin. Mol Cancer Res,
2010. 8(3): p. 407-420.
130. Seng, S., H.K. Avraham, G. Birrane, S. Jiang, and S. Avraham, Nuclear matrix protein
(NRP/B) modulates the nuclear factor (Erythroid-derived 2)-related 2 (NRF2)-dependent
oxidative stress response. J Biol Chem, 2010. 285(34): p. 26190-26198.
131. Jiang, S., Y. Fu, and H.K. Avraham, Regulation of hematopoietic stem cell trafficking
and mobilization by the endocannabinoid system. Transfusion, 2011. 51 Suppl 4: p. 71.
132. Li, H., J.T. Wood, K.M. Whitten, S.K. Vadivel, S. Seng, A. Makriyannis, and H.K.
Avraham, Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces
heme oxygenase 1 transcription in breast cancer cells. Br J Pharmacol, 2013. 170(3): p.
489-505.
26. HKA 26
133. Avraham, H.K., S. Jiang, Y. Fu, H. Nakshatri, H. Ovadia, and S. Avraham,
Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-
negative breast cancer cells in brain. J Pathol, 2014. 232(3): p. 369-381.
134. Avraham, H.K., S. Jiang, Y. Fu, E. Rockenstein, A. Makriyannis, A. Zvonok, E.
Masliah, and S. Avraham, The cannabinoid CB₂ receptor agonist AM1241 enhances
neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J
Pharmacol, 2014. 171(2): p. 468-479.
135. Rodriguez, P.L., S. Jiang, Y. Fu, S. Avraham, and H.K. Avraham, The proinflammatory
peptide substance P promotes blood-brain barrier breaching by breast cancer cells
through changes in microvascular endothelial cell tight junctions. Int J Cancer, 2014.
134(5): p. 1034-1044.
136. Avraham, H.K., S. Jiang, Y. Fu, E. Rockenstein, A. Makriyannis, J. Wood, L. Wang, E.
Masliah, and S. Avraham, Impaired Neurogenesis by HIV-1-Gp120 is Rescued by genetic
deletion of Fatty Acid Amide Hydrolase Enzyme. Br J Pharmacol, Feb 26, 2014.
Other Peer-Reviewed Publications
1. Avraham, H., M.H. Ellis, B.H. Jhun, S. Raja, D. Chalasani, and S. Avraham, Tyrosine
kinases in megakaryocytopoiesis. Stem Cells, 1995. 13(4): p. 380-92.
2. Ellis, M.H., H. Avraham, and J.E. Groopman, The regulation of megakaryocytopoiesis.
Blood Rev, 1995. 9(1): p. 1-6.
3. Avraham, S. and H. Avraham, Characterization of the novel focal adhesion kinase
RAFTK in hematopoietic cells. Leuk Lymphoma, 1997. 27(3-4): p. 247-56.
4. Avraham, H., S. Avraham, and Y. Taniguchi, Receptor protein tyrosine phosphatases in
hematopoietic cells. J Hematother Stem Cell Res, 2000. 9(4): p. 425-32.
5. Avraham, H., S.Y. Park, K. Schinkmann, and S. Avraham, RAFTK/Pyk2-mediated
cellular signalling. Cell Signal, 2000. 12(3): p. 123-33.
6. Avraham, H., S. Avraham, and R. Zagozdzon, Use of Antisense Oligonucleotide
Technology to Investigate Signaling Pathways in Megakaryocytes, in Platelets and
Megakaryocytes, J.M. Gibbins and M.P. Mahaut-Smith, Editors. 2004, Humana Press:
Totowa, NJ.
7. Jiang, S., Y. Fu, and H.K. Avraham, Regulation of hematopoietic stem cell trafficking
and mobilization by the endocannabinoid system. Transfusion, 2011. 51 Suppl 4: p. 65S-
71S.
Professional Education Materials or Reports in Print or Other Media
1. Avraham, H. and S. Avraham, Human Rho Gene Family, in Current Perspectives on
Molecular and Cellular Oncology: A Research Mannual, D.A. Spandidos, Editor. 1992,
JAI Press Limited: London. p. 197-209.
2. Price, D.J., Groopman, J.E., and H. Avraham, Megakaryocyte Signaling, in
Hematopoiesis: A Developmental Approach, L.I. Zon, Editor. 2001, Oxford University
Press: NY.
3. Avraham, H., S. Avraham, and R. Zagozdzon, Use of Antisense Oligonucleotide
Technology to Investigate Signaling Pathways in Megakaryocytes, in Platelets and
Megakaryocytes, J.M. Gibbins and M.P. Mahaut-Smith, Editors. 2002, Humana Press:
Totowa, NJ.
4. Avraham, H., S. Avraham, and R. Zagozdzon, Use of Antisense Oligonucleotide
27. HKA 27
Technology to Investigate Signaling Pathways in Megakaryocytes, in Platelets and
Megakaryocytes, J.M. Gibbins and M.P. Mahaut-Smith, Editors. 2004, Humana Press:
Totowa, NJ.
5. Avraham, H., Park, I., and D.J. Price, Protein Interactions, in Cancer Cell Signaling:
Methods and Protocols, D. Terrian and S.G. Pandalai, Editors. 2002, Humana Press:
Totowa, NJ. p. 255-268.
6. Park, S.Y., Avraham, H., and S. Avraham, Functional Aspects of RAFTK-Pyk2 in the
Nervous System, in Recent Research Developments in Neurochemistry, S.G. Pandalai,
Editor. 2002, Research Signpost: Kerala, India. p. 125-142.
7. Park, S.Y., Avraham, H., and S. Avraham, The Superfamily of Proteins Containing
Kelch and/or BTB Domains: from Cytoskeleton Dynamics to Transcriptional Regulation,
in Recent Research Developments in Neurochemistry, S.G. Pandalai, Editor. 2002,
Research Signpost: Kerala, India. p. 231-254.
8. Avraham, H., Hinton, C.V., Seng, S., Jiang, S., Avraham, R., and S. Avraham,
Mechanisms of VEGF-mediated Survival of Breast Cancer Cells, in Cancer Metastasis:
Recent Developments in Cancer, P. Rameshwar, Editor. 2007, Research Signpost: Kerala,
India.
9. Avraham, S., and H. Avraham, The Blood-Brain Barrier, in Encyclopedia of Cancer, M.
Schwab, Editor. 2007, Springer: NY.
10. Avraham, H., Hinton, C.V., Seng, S., Jiang, S., Avraham, R., and S. Avraham,
Mechanisms of VEGF-mediated Survival of Breast Cancer Cells, in Cancer Metastasis:
Recent Developments in Cancer, P. Rameshwar, Editor. 2010, Transworld Research
Network: Kerala, India.
11. Avraham, H.K., Jiang, S., Avraham, S., and A. Makriyannis, Regulation of Stem Cells
by the Endocannabinoid System, in Therapeutic Applications in Disease and Injury: Stem
Cells and Cancer Stem Cells, M.A. Hayat, Editor. 2012, Springer: NY.
12. Avraham, H.K., Jiang, S., Wang, L., Fu, Y., and S. Avraham, Cellular and Molecular
Mechanisms Involved in Breaching of the Blood-Brain Barrier by Circulating Breast
Cancer Cells, in Breast Cancer Metastasis and Drug Resistance: Challenges and
Progress, A. Ahmad, Editor. 2012, Springer: NY.
13. Avraham, S., Jiang, S., Wang, L., Fu, Y., and H.K. Avraham, VEGF-mediated Effects
on Brain Microvascular Endothelial Tight Junctions and Transmigration of Breast
Cancer Cells across the Blood-Brain Barrier, in Tight Junctions in Cancer Metastasis
(Cancer Metastasis - Biology and Treatment), T.A. Martin and W.G. Jiang, Editors. 2013,
Springer: NY. p. 247-261.
14. Avraham, H.K., Byeong-Chel, L., and S. Avraham, Colony-forming Unit Assay, in
Encyclopedic Reference of Immunotoxicology, H. Vohr, Editor. 2013, Springer: NY.
Thesis
Avraham, H.K., Development of a Radioimmunoassay for the Diagnosis of Malaria.
1983, Hebrew University of Jerusalem: Israel.
NARRATIVE REPORT
References cited are located under Report of Scholarship.
The major goals of my early career had been to conduct basic research to identify novel
genes and pathways regulating hematopoiesis. During the past 25 years, my focus has
28. HKA 28
been to determine the role of these genes in pathways in malignancy. My research is in
the area of signaling mechanisms that are essential for normal tissue growth and
development, but are perturbed in cancer. Specifically, my lab has focused on signaling
pathways of tyrosine kinases, such as CSK, CHK, SRC, FAK, RAFTK/Pyk2, ErbB-2 and
VEGF receptors in breast cancer cells and the identification of molecular mechanisms
important in breast cancer tumorigenesis and breast cancer metastasis to the brain.
In addition, my recent focus has been to study the molecular mechanisms for the
disproportionate incidence of triple-negative breast cancer (TNBC), characterized by a
lack of expression of the estrogen receptor, progesterone receptor and Her2/ErbB2, which
is more prevalent in African American (AA) and Hispanic women, as compared to
Caucasian women. Elucidation of novel mechanisms, and identification of novel
biomarkers, endogenous risk factors, and their targets that may contribute to the increased
mortality of AA women with breast cancer, is of high importance for reducing racial
disparities in breast cancer. Specifically, we have investigated the prostanoid signaling
pathways in TNBC tumor cells from AA and Caucasian women.
The main topics studied at my lab include:
I. Molecular mechanisms for breast cancer metastases to the brain
II. Role of BRCA1 and oxidative stress in sporadic and inherited breast cancer
III. Signal transduction pathways mediated by ErbB kinases, VEGF receptors, Src
kinases, Csk/CHK kinases and FAK/RAFTK/Pyk2 kinases in breast cancer cells
and their role in tumorigenesis and breast cancer metastasis
IV. VEGF-VEGFR 1 autocrine survival system and its role in chemotherapy
resistance
I, also, received a NIH-K18 award on stem cells. Therefore, during the last several years,
I have investigated new pathways that are important in hematopoietic and neural stem
cell survival and self-renewal, specifically focusing on the endocannabinoid system.
SUMMARY OF MAJOR ACTIVITIES AND RESEARCH ACHEIVEMENTS
My lab has made several seminal discoveries in the field of hematopoiesis and signaling
by tyrosine kinases and tyrosine phosphatases. Following my post-doctoral training at the
Weizmann Institute in Rehovot, Israel and the Whitehead Institute at the Massachusetts
Institute of Technology in Boston, I joined the Deaconess Hospital/Harvard Medical
School in 1989. My initial work was to characterize cytokine gene expression and
synthesis by human megakaryocytic cells. My laboratory, a pioneer group, was one of the
first to demonstrate the role of the c-kit ligand in the interaction of human bone marrow
fibroblasts with megakaryocytes [16,19]. In addition, we elucidated the effects of
transforming growth factor beta, SCF/c-kit ligand and thrombopoietin on megakaryocytes
and platelet formation.
Next, I focused my efforts on new gene discovery. We have been successful not only in
identifying new genes but also in characterizing their functions. Some of our most
important discoveries were:
29. HKA 29
I. The protein tyrosine kinases CHK [23,27,30] and RAFTK [28,32]
II. The protein tyrosine phosphatases PTP-NP-2 [47,63, 104] and PTP-RO [37,59]
III. Identification of Flt-4 [31]
IV. The novel Kelch-related proteins: NRP/B, Mayven, and MRP2, which were
studies performed in collaboration with Dr. Shalom Avraham)
[48,58,98,100,110,116]
These were all novel genes expressed in hematopoietic cells and/or brain, and were
shown to be important molecules in cell signaling pathways.
CHK
The Csk homologous kinase (CHK) was cloned first by our group. CHK expression is
restricted to hematopoietic cells and the nervous system. We demonstrated that CHK
phosphorylates the inhibitory C-terminal tyrosine of several Src-family kinases in vitro,
and importantly interacts with c-kit in megakaryocytes. Recently, we identified
MATK/CHK as an essential regulator of immune cells using Matk/CHK-deficient mice
[107]. Interestingly, we also discovered that CHK is a unique negative regulator of breast
cancer cell growth and that it associates with ErbB-2 upon heregulin stimulation in breast
cancer cells. This project has been supported significantly by the NIH, the Department of
Defense, and the Commonwealth of Massachusetts.
In summary, we found that CHK binds specifically to the cytoplasmic tail of ErbB-2, the
overexpressed oncogene that is a major target in breast cancer therapeutics [45,52,68].
We demonstrated that CHK has an anti-oncogene activity of blocking growth signaling
by heregulin (the ligand for ErbB-2). The NMR structure of CHK with the tail of ErbB-2
was also solved [74]. This structural information allows the design of small molecules to
mimic the activity of CHK and block breast cancer growth by shutting down ErbB-2
signaling. Lastly, we generated CHK transgenic mice and showed the role of Src kinases
in Neu-induced tumorigenesis. Our data, using CHK as a physiologic inhibitor of Src
activity, showed that blocking of Neu-induced Src activity without altering Src
expression levels had no significant effects on Neu-mediated mammary tumorigenesis in
vivo [105]. This contradicts the current paradigm that activation of Src kinases is essential
for Neu-induced oncogenesis. This study was the first to distinguish between the kinase-
dependent and kinase-independent actions of Src and showed that its kinase-dependent
properties are not requisite for Neu-induced tumorigenesis.
We also found that CHK in brain modulates the signaling of the Trk-A receptor following
nerve growth factor (NGF) stimulation [61]. Our discovery on CHK showed differential
expression of CHK in normal brain and brain tumors [90].
RAFTK/Pyk2
Our lab was central in the cloning and identification of RAFTK/Pyk2, a signaling
molecule that coordinates cytokine, chemokine and integrin-mediated signaling in
megakaryocytes, platelets and other blood cells. Of note, RAFTK appears to be a target
of HIV in T-cells and macrophages. RAFTK serves as a critical “platform kinase” upon
30. HKA 30
which a variety of signaling molecules interact, including adaptor proteins, Src kinase,
phosphatases, and cytoskeletal elements. RAFTK was shown to play critical signaling
roles in a variety of essential cell functions like chemotaxis, cell adhesion, and apoptosis
[28,32,34,35,36,39,43,63,64]. In addition, we have demonstrated that RAFTK is involved
in breast cancer invasion [65,97].
My lab also showed that vascular endothelial growth factor regulated focal adhesion
assembly in human brain microvascular endothelial cells through activation of
RAFTK/Pyk2 [83].
MOLECULAR MECHANISMS FOR BREAST CANCER CELL INVASION AND
MIGRATION
While investigating the molecular mechanisms of breast cancer cell invasion and
metastasis, we discovered unique roles of VEGF and the CXCR4/CXCL12 axis in breast
cancer cell invasion and migration. We reported that vascular endothelial growth factor
modulates the transendothelial migration of MDA-MB-231 breast cancer cells through
regulation of brain microvascular endothelial cell permeability [75]. We reported the
involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor
1alpha in breast cancer cell migration through human brain microvascular endothelial
cells [92]. We also discovered a unique role of CHK kinase in negatively regulating the
chemokine receptor CXCR4 through YY1 and impaired CXCR4/CXCL12 (SDF-1alpha)-
mediated breast cancer cell migration [101].
ROLE OF BRCA1 IN SPORADIC AND INHERITED BREAST CANCER
We also investigated several aspects of BRCA1, the breast cancer susceptibility gene.
Our studies showed that BRCA1 is modulated through heregulin binding to the ErbB-2
receptor via the PI-3 kinase/AKT pathway [52]. We also identified novel proteins
associated with BRCA1 genes using the yeast two-hybrid system. BRCA1 encodes a
nuclear phosphoprotein that acts as a tumor suppressor, while activation of the ErbB
receptors by heregulin (HRG) promotes cell growth in breast epithelial cells. The
possibility that ErbB-2 receptor activation by heregulin can modulate BRCA1 function
presents a new approach and a novel mechanism for understanding breast cancer biology.
In addition, we have shown that BRCA1 forms a novel complex with Nmi and c-Myc and
inhibits c-Myc induced Telomerase activity [76]. We also discovered that the
extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and
suppresses BRCA1 expression through its C-terminus [86]. We next showed that cell
cycle-dependent DNA damage signaling induced by ICRF-193 involves ATM, ATR,
CHK2, and BRCA1. The DNA damage signaling induced by ICRF-193 was mediated by
ATM and ATR and was restricted to cells in specific cell cycle stages such as S, G2, and
mitosis including late and early G1 phases. Downstream signaling of ATM and ATR
involved the phosphorylation of CHK2 and BRCA1 [109].
Effects of Cannabinoids on Profiling and Pathways of Neural Stem Cell Niches in
NeuroAIDS/HIV:
31. HKA 31
Neural progenitor cells (NPCs) are critical for brain development and response to injury
and inflammation. Emerging reports suggest that NPCs are involved in the
neuropathogenesis of HAD and are targeted in HIV-mediated toxicity. However, it is not
known how HIV-1 and HIV-1 viral proteins (such as Gp120) cause damage to NPCs. We
hypothesize that cognitive dysfunction in the setting of HIV infection is related to
alterations in hippocampal neurogenesis, resulting in molecular changes of adult
neurogenesis; Further, since cannabinoids were reported to have neuroprotective effects,
we suggest that HIV-1 mediated toxicity of NPCs is inhibited by endocannabinoids by
increasing NPC survival and proliferation, resulting in increased neurogenesis. In this
project we aim to determine the pathways and molecular profiling by which HIV-1
mediates damage to NPC niches in NeuroAIDS/HIV. Using novel in vivo mice models
for HAD and autopsy samples from brain of patients with HAD, proteomic modeling and
three-dimensional whole mounts, confocal microscopy, and automated computer-based
image quantification, will be employed to examine the NPCs within their adult
subventricular zone niches following exposure to HIV-1 Gp120 and HIV-1 infection. In
addition, we aim to examine the protective effects of endocannabinoids in inhibiting
HIV-1 mediated injury on neurogenesis using in vivo mice models.
Understanding of how HIV affects both molecular and cellular aspects of neurogenesis
should lead to the development of more effective therapeutic interventions for HAD and
for the eradication of HIV reservoirs in brain.